# Patent

## Title
Protein subcellular localization assays using split fluorescent proteins

## Abstract

The invention provides protein subcellular localization assays using split fluorescent protein systems. The assays are conducted in living cells, do not require fixation and washing steps inherent in existing immunostaining and related techniques, and permit rapid, non-invasive, direct visualization of protein localization in living cells. The split fluorescent protein systems used in the practice of the invention generally comprise two or more self-complementing fragments of a fluorescent protein, such as GFP, wherein one or more of the fragments correspond to one or more beta-strand microdomains and are used to “tag” proteins of interest, and a complementary “assay” fragment of the fluorescent protein. Either or both of the fragments may be functionalized with a subcellular targeting sequence enabling it to be expressed in or directed to a particular subcellular compartment (i.e., the nucleus).

## Background
RELATED APPLICATION
This patent application claims the benefit of the filing date of U.S. Provisional patent application No. 60/633,488, filed Dec. 4, 2004. The subcellular localization assays of the invention utilize split-fluorescent and split-chromophoric protein systems, which are described in co-owned, co-pending U.S. patent application Ser. No. 10/973,693, entitled “SELF-ASSEMBLING SPLIT-FLUORESCENT PROTEIN SYSTEMS”, filed Oct. 25, 2004 and hereby incorporated by reference in its entirety.


STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
This invention was made with government support under Contract No. W-7405-ENG-36 awarded by the United States Department of Energy to The Regents of The University of California. The government has certain rights in this invention.


BACKGROUND OF THE INVENTION
Understanding the intracellular transport and localization of proteins is important because many processes in biology, including transcription, translation, and metabolic or signal transduction pathways, are mediated by proteins and non-covalently-associated multiprotein complexes localized to particular cellular compartments Reed, L. J. (1974) Multienzyme Complexes. Acc. Chem. Res. 7, 40-46. Proteins and protein complexes are the workhorses of the chemical machinery in living systems and define the interface between metabolic pathways, signaling pathways, and the response of cells to the environment. Since the completion of the genome sequencing projects, the focus of biological research has moved to identifying proteins involved in cellular processes, determining their functions and how, when, and where they localize to facilitate interaction with other proteins involved in specific pathways. Further, with rapid advances in genome sequencing projects there is a need to develop strategies to define “protein linkage maps”, detailed inventories of protein interactions that make up functional assemblies of proteins Lander, E. S. (1996) The new genomics—global views of biology. Science 274, 536-539; Evangelista, C., Lockshon, D. & Fields, S. (1996) The yeast two-hybrid system—prospects for protein linkage maps. Trends in Cell Biology 6, 196-199. Eukaryotic cells have specialized compartments containing specific proteins needed to carry out defined processes. Understanding when and where specific proteins localize is key to further understanding of cellular processes.
GFP and its numerous related fluorescent proteins are now in widespread use as protein tagging agents (for review, see Verkhusha et al., 2003, GFP-like fluorescent proteins and chromoproteins of the class Anthozoa. In: Protein Structures: Kaleidescope of Structural Properties and Functions, Ch. 18, pp. 405-439, Research Signpost, Kerala, India), and have been used to visualize protein trafficking in living cells (Llopis, McCaffery et al. 1998; Southward and Surette 2002). Generally, using existing methodologies, a gene of interest is expressed in fusion with GFP and the fusion protein localizes fluorescence to the normal localization of the target protein. The fusion protein may be encoded by a constitutive promoter on a plasmid or may be directly transfected into the cell by any transfection methodology (FIG. 1). A number of localization vectors expressing fluorescent proteins fused to subcellular localization sequences or tags have been described and/or are commercially available (e.g., the Living ColorsTM localization vectors, BD Biosciences Clontech, Palo Alto, Calif.)
However, although protein localization methods using GFP fused to a protein of interest have been useful, these methods provide limited information and are compromised by problems inherent in using a relatively large terminally fused reporter protein tag. In particular, GFP and related fluorescent proteins may cause misfolding of the fused protein, and may interfere with protein processing and/or intracellular transport. Misfolding of the reporter can result in the generation of insoluble aggregates of the fusion, which may be unable to freely move through intracellular processing and transport systems within the cell. Additionally, GFP fusions may alter biophysical properties of a test protein, resulting in a default in the corresponding localization pathway (Hanson and Ziegler, 2004). In general, the use of GFP fusions in extracytoplasmic compartments has been limited because of export deficiencies. As an example, efforts to obtain functional GFP following export through the sec-dependent pathway failed because of improper folding of the protein; the secreted fraction of GFP was not fluorescent (Feilmeier, Iseminger et al. 2000; Tanudji, Hevi et al. 2002). Accordingly, it is difficult to obtain a true picture of a test protein's trafficking or distribution within a cell using terminal GFP fusion tags, and systems capable of visualizing subcellular compartmentalization through a wider lens and over time are needed.
GFP fragment reconstitution systems have been described, mainly for detecting protein-protein interactions, but none are capable of unassisted self-assembly into a correctly-folded, soluble and fluorescent re-constituted GFP, and no general split GFP folding reporter system has emerged from these approaches. For example, Ghosh et al, 2000, reported that two GFP fragments, corresponding to amino acids 1-157 and 158-238 of the GFP structure, could be reconstituted to yield a fluorescent product, in vitro or by coexpression in E. coli, when the individual fragments were fused to coiled-coil sequences capable of forming an antiparallel leucine zipper (Ghosh et al., 2000, Antiparallel leucine zipper-directed protein reassembly.: application to the green fluorescent protein. J. Am. Chem. Soc. 122: 5658-5659). Likewise, U.S. Pat. No. 6,780,599 describes the use of helical coils capable of forming anti-parallel leucine zippers to join split fragments of the GFP molecule. The patent specification establishes that reconstitution does not occur in the absence of complementary helical coils attached to the GFP fragments. In particular, the specification notes that control experiments in which GFP fragments without leucine zipper pairs “failed to show any green colonies, thus emphasizing the requirement for the presence of both NZ and CZ leucine zippers to mediate GFP assembly in vivo and in vitro.”
Similarly, Hu et al., 2002, showed that the interacting proteins bZIP and Rel, when fused to two fragments of GFP, can mediate GFP reconstitution by their interaction (Hu et al., 2002, Visualization of interactions among bZIP and Rel family proteins in living cells using bimolecular fluorescence complementation. Mol. Cell 9: 789-798). Nagai et al., 2001, showed that fragments of yellow fluorescent protein (YFP) fused to calmodulin and M13 could mediate the reconstitution of YFP in the presence of calcium (Nagai et al., 2001, Circularly permuted green fluorescent proteins engineered to sense Ca2+. Proc. Natl. Acad. Sci. USA 98: 3197-3202). In a variation of this approach, Ozawa at al. fused calmodulin and M13 to two GFP fragments via self-splicing intein polypeptide sequences, thereby mediating the covalent reconstitution of the GFP fragments in the presence of calcium (Ozawa et al., 2001, A fluorescent indicator for detecting protein-protein interactions in vivo based on protein splicing. Anal. Chem. 72: 5151-5157; Ozawa et al., 2002, Protein splicing-based reconstitution of split green fluorescent protein for monitoring protein-protein interactions in bacteria: improved sensitivity and reduced screening time. Anal. Chem. 73: 5866-5874). One of these investigators subsequently reported application of this splicing-based GFP reconstitution system to cultured mammalian cells (Umezawa, 2003, Chem. Rec. 3: 22-28). More recently, Zhang et al., 2004, showed that the helical coil split GFP system of Ghosh et al., 2000, supra, could be used to reconstitute GFP (as well as YFP and CFP) fluorescence when coexpressed in C. elegans, and demonstrated the utility of this system in confirming coexpression in vivo (Zhang et al., 2004, Combinatorial marking of cells and organelles with reconstituted fluorescent proteins. Cell 119: 137-144).
Although the aforementioned GFP reconstitution systems provide advantages over the use of two spectrally distinct fluorescent protein tags, they are limited by the size of the fragments and correspondingly poor folding characteristics (Ghosh et al., Hu et al., supra), the requirement for a chemical ligation or fused interacting partner polypeptides to force reconstitution (Ghosh et al., 2000, supra; Ozawa et al., 2001, 2002 supra; Zhang et al., 2004, supra), and co-expression or co-refolding to produce detectable folded and fluorescent GFP (Ghosh et al., 2000; Hu et al., 2001, supra). Poor folding characteristics limit the use of these fragments to applications wherein the fragments are simultaneously expressed or simultaneously refolded together. Such fragments are not useful for in vitro assays requiring the long-term stability and solubility of the respective fragments prior to complementation. An example of an application for which such split protein fragments are not useful would be the quantification of polypeptides tagged with one member of the split protein pair, and subsequently detected by the addition of the complementary fragment.
SUMMARY OF THE INVENTION
The invention provides protein subcellular localization assays using split fluorescent protein systems. The assays are conducted in living cells, do not require fixation and washing steps inherent in existing immunostaining and related techniques, and permit rapid, non-invasive, direct visualization of protein localization in living cells. The split fluorescent protein systems used in the practice of the invention generally comprise two or more self-complementing fragments of a fluorescent protein, such as GFP, wherein one or more of the fragments correspond to one or more beta-strand microdomains and are used to “tag” proteins of interest, and a complementary “assay” fragment of the fluorescent protein. Either or both of the fragments may be functionalized with a subcellular targeting sequence enabling it to be expressed in or directed to a particular subcellular compartment (i.e., the nucleus).
In general terms, the invention provides a suite of assays that can be used to detect and differentiate the subcellular location of a protein of interest in living cells, detect proteins that interact in defined subcellular compartments, track the transport of proteins through and out of the cell, identify cell surface expression, monitor and quantify protein secretion, and screen for mediators of localization, transport and/or secretion. These assays may also be used in combination with directed evolution strategies, and scaled to high-throughput screening of protein variants with modified subcellular localization characteristics. The assays are useful to visualize protein localization in, for example, the nucleus, cytoplasm, plasma membrane, endoplasmic reticulum, golgi apparatus, filaments or microtubules such as actin and tubulin filaments, endosomes, peroxisomes and mitochondria.
In one particular embodiment, a test protein is fused to a sixteen amino acid fragment of GFP (β-strand 11, amino acids 215-230), engineered to not perturb fusion protein solubility. When the complementary “assay” GFP fragment (β-strands 1 through 10, amino acids 1-214) is provided, spontaneous association of the GFP fragments results in structural complementation, folding, and concomitant GFP fluorescence. In some embodiments, the assay fragment is functionalized with a subcellular targeting sequence of interest, such that the fragment is localized to the subcellular element of interest, following expression of the fragment in the cell or transfection into the cell. If the test protein is expressed in the cell, or transfected into the cell, and becomes localized to the subcellular element of interest, the fragments self-complement and generate a visually detectable fluorescence. Non-imaging fluorescence detection can be used to determine if the cell has increased fluorescence, thereby indicating that the localization has occurred in the particular compartment to which the complementing fragments have been directed. If desired, imaging fluorescence microscopy is used to visualize the resulting, specifically-localized fluorescent signal, further confirming the presence of the test protein in the subcellular element of interest.
The subcellular localization assays of the invention are simple and only require the use of instruments and methods capable of visualizing fluorescence, such as various well known fluorescence microscopy, confocal microscopy, video microscopy techniques, and the like. The assays require no external reagents, and can be conducted in living cells, enabling real-time imaging in cells with minimal intervention.
A distinct advantage of the present invention over tagging using full-length GFP is the absence of background fluorescence prior to complementation. Only if complementation occurs in a particular compartment to which one or more fragments are localized, does that compartment become fluorescent. It is necessary only to measure the fluorescence of the cell to determine whether the specific localization has occurred, enabling high-throughput screens using flow cytometry, for example, without the need to specifically visualize all the structures in the cell by microscopy. In contrast, when proteins are tagged with full-length GFP, the proteins are fluorescent regardless of localization, and imaging or microscopy must be used to determine the subcellular localization of the tagged protein.



BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows principle of split GFP self-complementation. A protein of interest (X) is fused to a small GFP fragment (β-strand 11, residues 215-230) via a flexible linker (L). The complementary GFP fragment (β-strands 1-10, residues 1-214) is expressed separately. Neither fragment alone is fluorescent. When mixed, the small and large GFP fragments spontaneously associate, resulting in GFP folding and formation of the fluorophore. Processes that make the small GFP tag inaccessible, such as misfolding or aggregation, can prevent complementation.
FIG. 2 depicts protein localization using full length GFP. The protein of interest X is expressed in fusion with GFP. The fluorescence of the fusion enables tracking the localization of the protein X in the cell. However, the fusion may not be soluble (C) and will fail to migrate freely in the cell due to aggregation of the fusion protein.
FIG. 3 depicts protein localization studies using a split fluorescent protein, e.g., GFP. The protein of interest X is expressed in fusion with a non-perturbing GFP s11 fragment. In parallel, the large s1-10 GFP fragment is expressed from an independent plasmid. When the transfected GFP s11 tagged protein and the s1-10 GFP fragment meet in the cell, complementation of the two moieties GFP s11+s1-10 induces fluorescence and localization of the protein X in the cell. Unlike fusions with full-length GFP (FIG. 2), GFP s11 has no perturbing effect on the fused protein.
FIG. 4 depicts an assay for screening mitochondrial protein localization. GFP s-10 assay fragment bearing the mitochondrial localization tag is expressed from a constitutive plasmid or transfected into the cell. The presence of the localization signal directs the assay fragment to mitochondria. In parallel, the target proteins (random library) in fusions with a GFP s11 tag fragment are expressed from an inducible expression vector. Localization of the fusion will be targeted to the specialized compartment if the fragment contains a mitochondrial localization signal. Complementation between the pre-localized assay fragment and the expressed fusion X-GFP s11 results in fluorescence in the mitochondria.
FIG. 5 shows timing the expression of a protein. Cell lines express constitutively the target protein X in fusion with GFP s11. At desired times, an excess of a complementary assay fragment with a C-terminal destabilizing tag is transfected into the cell. The newly synthesized GFP s11 tagged molecules are detected by complementation (FIG. 5, A). Complementation occurs until the GFP s1-10 destabilized fragment is degraded. Once degraded, cells are incubated in growth media for several hours and the procedure is repeated with another destabilized GFP s1-10 assay fragment variant producing a different color upon complementation with GFP s11, for example red (FIG. 5, B). After several assay fragment transfection cycles, superimposition of the different images, taken for each of the excitation/emission wavelengths characteristic of the assay fragments used, would enable localization of the older synthesized protein molecules from the newer synthesized ones (FIG. 5, C).
FIG. 6 shows the topological secondary structure diagram of the eleven beta-stranded GFP family members. (A) Strands and numbering of amino acids. Circled number corresponds to index of the turn between strands (and a preferred site for splitting the protein), dark circles are the folding reporter mutations, and white circles are the superfolder GFP mutations. (B) shows numbering convention of the eleven beta strands. (C) shows a circular permutant GFP made by connecting the N and C termini by a short flexible linker and providing a new start codon at amino acid 173, and stop codon after amino acid 172.
FIG. 7A shows a schematic diagram of the pTET-SpecR plasmid, which is a modified version of the pPROTet.6×HN vector available from Clontech (Palo Alto, Calif.). The chloramphenicol resistance gene was replaced by the spectinomycin resistance marker under the control of the kanamycin promoter of the pPROlar resistance marker (pPROlar plasmid from Clontech, Palo Alto, Calif.). On the same cistron is encoded the tetracycline repressor upstream of the TO transcription termination sequence. The amount of translated repressor is regulated by a weak Shine-Delgarno sequence downstream of SacI.
FIG. 7B shows the different elements of the engineered pTET-SpecR plasmid [SEQ ID NO: 22]. Regions of interest are boxed: Box 1=v1 cloning cassette for expressing genes under tet promoter, flanked by NcoI CCATGG, and KpnI GGTACC. Box 2=T0 transcription terminator for the SpecR-tetR cistron; Box 3=tetR repressor gene; Box 4=RBS controlling tetR translation; Box 5=spectinomycin (specR) gene; Cyan=kanamycin promoter element from PROLAR vector (Clontech, Palo Alto, Calif.).



DETAILED DESCRIPTION OF THE INVENTION
Definitions
Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodology by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 3rd. edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. and Current Protocols in Molecular Biology (Ausbel et al., eds., John Wiley & Sons, Inc. 2001. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer defined protocols and/or parameters unless otherwise noted.
A “fluorescent protein” as used herein is an Aequorea Victoria green fluorescent protein (GFP), structural variants of GFP (i.e., circular permutants, monomeric versions), folding variants of GFP (i.e., more soluble versions, superfolder versions), spectral variants of GFP (i.e., YFP, CFP), and GFP-like fluorescent proteins (i.e., DsRed). The term “GFP-like fluorescent protein” is used to refer to members of the Anthozoa fluorescent proteins sharing the 11-beta strand “barrel” structure of GFP, as well as structural, folding and spectral variants thereof. GFP-like proteins all share common structural and functional characteristics, including without limitation, the capacity to form internal chromophores without requiring accessory co-factors, external enzymatic catalysis or substrates, other than molecular oxygen.
A “variant” of a fluorescent protein is derived from a “parent” fluorescent protein and retains the 11 beta-strand barrel structure as well as intrinsic fluorescence, and is meant to include structures with amino acid substitutions, deletions or insertions that may impart new or modified biological properties to the protein (i.e., greater stability, improved solubility, improved folding, shifts in emission or excitation spectra, reduced or eliminated capacity to form multimers, etc) as well as structures having modified N and C termini (i.e., circular permutants).
The term “complementing fragments” or “complementary fragments” when used in reference to a reporter polypeptide refer to fragments of a polypeptide that are individually inactive (i.e., do not express the reporter phenotype), wherein binding of the complementing fragments restores reporter activity. The terms “self-complementing”, “self-assembling”, and “spontaneously-associating”, when used to describe two or more fluorescent (or chromophoric) protein fragments, mean that the fragments are capable of reconstituting into an intact, fluorescent (or chromophoric) protein when the individual fragments are soluble.
The terms “subcellular compartment”, “subcellular element”, and “subcellular location” are used to refer to various distinguishable parts, components or organelles of a cell, including without limitation, the nucleus, cytoplasm, plasma membrane, endoplasmic reticulum, golgi apparatus, filaments such as actin and tubulin filaments, endosomes, peroxisomes and mitochondria.
The “MMDB Id: 5742 structure” as used herein refers to the GFP structure disclosed by Ormo & Remington, MMDB Id: 5742, in the Molecular Modeling Database (MMDB), PDB Id: 1EMA PDB Authors: M. Ormo & S. J. Remington PDB Deposition: 1 Aug. 1996 PDB Class: Fluorescent Protein PDB Title: Green Fluorescent Protein From Aequorea Victoria. The Protein Data Bank (PDB) reference is Id PDB Id: 1 EMA PDB Authors: M. Ormo & S. J. Remington PDB Deposition: 1 Aug. 1996 PDB Class: Fluorescent Protein PDB Title: Green Fluorescent Protein From Aequorea Victoria. (see, e.g., Ormo et al. “Crystal structure of the Aequorea victoria green fluorescent protein.” Science Sep. 6, 1996;273(5280):1392-5; Yang et al, “The molecular structure of green fluorescent protein.” Nat Biotechnol. Oct. 14, 1996(10):1246-51).
“Root mean square deviation” (“RMSD”) refers to the root mean square superposition residual in Angstroms. This number is calculated after optimal superposition of two structures, as the square root of the mean square distances between equivalent C-alpha-atoms.
The term “heterologous” when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, a nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a nucleic acid encoding a fluorescent protein from one source and a nucleic acid encoding a peptide sequence from another source. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).
The terms “identical” or percent “identity”, in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 70% identity, preferably 75%, 80%, 85%, 90%, or 95% identity over a specified region, when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection. Such sequences are then said to be “substantially identical.” This definition also refers to the compliment of a test sequence. Preferably, the identity exists over a region that is at least about 22 amino acids or nucleotides in length, or more preferably over a region that is 30, 40, or 50-100 amino acids or nucleotides in length.
For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
A “comparison window”, as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, 1981, Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman & Wunsch, 1970, J. Mol. Biol. 48:443, by the search for similarity method of Pearson & Lipman, 1988, Proc. Nat'l. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al., eds. 1995 supplement)).
A preferred example of algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., 1977, Nuc. Acids Res. 25:3389-3402 and Altschul et al., 1990, J. Mol. Biol. 215:403-410, respectively. BLAST and BLAST 2.0 are used, typically with the default parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, an expectation (E) of 10, M=5, N=−4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a word length of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=−4, and a comparison of both strands.
The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, 1993, Proc. Nat'l. Acad. Sci. USA 90:5873-5787). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.
The term “as determined by maximal correspondence” in the context of referring to a reference SEQ ID NO means that a sequence is maximally aligned with the reference SEQ ID NO over the length of the reference sequence using an algorithm such as BLAST set to the default parameters. Such a determination is easily made by one of skill in the art.
The term “link” as used herein refers to a physical linkage as well as linkage that occurs by virtue of co-existence within a biological particle, e.g., phage, bacteria, yeast or other eukaryotic cell.
“Physical linkage” refers to any method known in the art for functionally connecting two molecules (which are termed “physically linked”), including without limitation, recombinant fusion with or without intervening domains, intein-mediated fusion, non-covalent association, covalent bonding (e.g., disulfide bonding and other covalent bonding), hydrogen bonding; electrostatic bonding; and conformational bonding, e.g., antibody-antigen, and biotin-avidin associations.
“Fused” refers to linkage by covalent bonding.
As used herein, “linker” or “spacer” refers to a molecule or group of molecules that connects two molecules, such as a fluorescent binding ligand and a display protein or nucleic acid, and serves to place the two molecules in a preferred configuration.
The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.
The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
The term “nucleic acid” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides which have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g. degenerate codon substitutions) and complementary sequences and as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., 1991, Nucleic Acid Res. 19: 5081; Ohtsuka et al., 1985 J. Biol. Chem. 260: 2605-2608; and Cassol et al., 1992; Rossolini et al., 1994, Mol. Cell. Probes 8: 91-98). The term nucleic acid is used interchangeably with gene, cDNA, and mRNA encoded by a gene.
“Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.
As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.
The following eight groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).
Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts et al., Molecular Biology of the Cell (3rd ed., 1994) and Cantor and Schimmel, Biophysical Chemistry Part I: The Conformation of Biological Macromolecules (1980). “Primary structure” refers to the amino acid sequence of a particular peptide. “Secondary structure” refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that form a compact unit of the polypeptide and are typically 25 to approximately 500 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of β-sheet and α-helices. “Tertiary structure” refers to the complete three dimensional structure of a polypeptide monomer. “Quaternary structure” refers to the three dimensional structure formed by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.
The terms “isolated” and “purified” refer to material which is substantially or essentially free from components which normally accompany it as found in its native state. However, the term “isolated” is not intended refer to the components present in an electrophoretic gel or other separation medium. An isolated component is free from such separation media and in a form ready for use in another application or already in use in the new application/milieu.
Split-Fluorescent and Chromophoric Protein Systems
The subcellular localization assays of the invention utilize split-fluorescent and split-chromophoric protein systems, which are described in co-owned, co-pending U.S. patent application Ser. No. 10/973,693, entitled “SELF-ASSEMBLING SPLIT-FLUORESCENT PROTEIN SYSTEMS”, filed Oct. 25, 2004 and hereby incorporated by reference in its entirety.
In the practice of the protein subcellular localization assays of the invention, a number of different split-fluorescent protein systems may be utilized. In general, the split fragments should be capable of being folded and soluble in the cellular environment. In preferred embodiments, the folding/solubility of individual fragments is tested in the cell to be utilized, and optionally evolved, in order to isolate soluble “tag” fragment(s) and soluble “assay” fragment(s). In preferred applications, the tag fragment is a fluorescent protein microdomain corresponding to a single beta-strand (i.e., GFP s11) that is substantially non-perturbing to fused test proteins. The tag fragment (in fusion with a test protein) may be functionalized with pre-defined subcellular localization signals. The use of a single beta-strand provides a tag that is non-perturbing to fused test protein solubility, and minimizes the potential for interference with cellular processing and transport of the fusion. The assay fragment, to which pre-defined subcellular localization signals may be fused, will be structurally complementary to the tag fragment (i.e. GFP s1-10), soluble in the cell used in the assay, and available for complementation with a co-localized tag-test protein fusion protein. The assay fragment is ideally monomeric, and should not spontaneously aggregate or misfold.
A number of specifically engineered tag and assay fragments of a GFP variant are disclosed in U.S. application Ser. No. 10/973,693, supra, the structures of which (DNA and AA sequences) are reproduced herein under the Table of Sequences subsection, infra. Additionally, vectors sequences designed for use with split-GFP systems are also reproduced in the same subsection, infra.
Preferred split-fluorescent protein systems for use in the practice of the assays and methods of the invention are those derived from GFP and GFP-like proteins. GFP-like proteins are an expanding family of homologous, 25-30 kDa polypeptides sharing a conserved 11 beta-strand “barrel” structure. The GFP-like protein family currently comprises some 100 members, cloned from various Anthozoa and Hydrozoa species, and includes red, yellow and green fluorescent proteins and a variety of non-fluorescent chromoproteins (Verkhusha et al., supra). A wide variety of fluorescent protein labeling assays and kits are commercially available, encompassing a broad spectrum of GFP spectral variants and GFP-like fluorescent proteins, including cyan fluorescent protein, blue fluorescent protein, yellow fluorescent protein, etc., DsRed and other red fluorescent proteins (Zimmer, 2002, Chem. Rev. 102: 759-781; Zhang et al., 2002, Nature Reviews 3: 906-918; Clontech, Palo Alto, CA; Amersham, Piscataway, N.J.). Typically, GFP variants share about 80%, or greater sequence identity with wild type GFP. Color-shift GFP mutants have emission colors blue to yellow-green, increased brightness, and photostability (Tsien, 1998, Annual Review of Biochemistry 67: 509-544).
Additional GFP-based variants having modified excitation and emission spectra (Tsien et al., U.S. Patent Appn. 20020123113A1), enhanced fluorescence intensity and thermal tolerance (Thastrup et al., U.S. Patent Appn. 20020107362A1; Bjorn et al., U.S. Patent Appn. 20020177189A1), and chromophore formation under reduced oxygen levels (Fisher, U.S. Pat. No. 6,414,119) have also been described. GFPs from the Anthozoans Renilla reniformis and Renilla kollikeri have also been described (Ward et al., U.S. Patent Appn. 20030013849).
One widely utilized red fluorescent protein was isolated from Discosoma species of coral, DsRed (Matz et al., 1999, Nat. Biotechnol. 17:969-973), and various DsRed variants (e.g., DsRed1, DsRed2) have been described. DsRed and the other Anthozoa fluorescent proteins share only about 26-30% amino acid sequence identity to the wild-type GFP from Aequorea victoria, yet all the crucial motifs are conserved, indicating the formation of the 11-stranded beta-barrel structure characteristic of GFP. The crystal structure of DsRed has also been solved, and shows conservation of the 11-stranded beta-barrel structure of GFP MMDB Id: 5742.
A number of mutants of the longer wavelength red fluorescent protein DsRed have also been described. For example, recently described DsRed mutants with emission spectra shifted further to the red may be employed in the practice of the invention (Wiehler et al., 2001, FEBS Letters 487: 384-389; Terskikh et al., 2000, Science 290: 1585-1588; Baird et al., 2000, Proc. Natl. Acad. Sci. USA 97: 11984-11989). Recently, a monomeric variant of DsRed was described (Campell et al., 2002, Proc. Natl. Acad. Sci USA 99: 7877-7882). This variant, termed “mRFP1”, matures quickly (in comparison to wild type DsRed, which matures over a period of 30 hours), has no residual green fluorescence, and has excitation and emission wavelengths of about 25 nm longer than other DsRed variants.
An increasingly large number of other fluorescent proteins from a number of ocean life forms have recently been described, and the Protein Data Bank currently lists a number of GFP and GFP mutant crystal structures, as well as the crystal structures of various GFP analogs. Related fluorescent proteins with structures inferred to be similar to GFP from corals, sea pens, sea squirts, and sea anemones have been described, and may be used in the generation of the split-fluorescent protein systems of the invention (for reviews, see Zimmer, 2002, Chem. Rev. 102: 759-781; Zhang et al., 2002, Nature Reviews 3: 906-918).
Additionally, fluorescent proteins from Anemonia majano, Zoanthus sp., Discosoma striata, Discosoma sp. and Clavularia sp. have also been reported (Matz et al., supra). A fluorescent protein cloned from the stony coral species, Trachyphyllia geoffroyi, has been reported to emit green, yellow, and red light, and to convert from green light to red light emission upon exposure to UV light (Ando et al., 2002, Proc. Natl. Acad. Sci. USA 99: 12651-12656). Recently described fluorescent proteins from sea anemones include green and orange fluorescent proteins cloned from Anemonia sulcata (Wiedenmann et al., 2000, Proc. Natl. Acad. Sci. USA 97: 14091-14096), a naturally enhanced green fluorescent protein cloned from the tentacles of Heteractis magnifica (Hongbin et al., 2003, Biochem. Biophys. Res. Commun. 301: 879-885), and a generally non fluorescent purple chromoprotein displaying weak red fluorescence cloned from Anemonia sulcata, and a mutant thereof displaying far-red shift emission spectra (595 nm) (Lukyanov et al., 2000, J. Biol. Chem. 275: 25879-25882).
A recently described red fluorescent protein isolated from the sea anenome Entacmaea quadricolor, EqFP611, is a far-red, highly fluorescent protein with a unique co-planar and trans chromophore (Wiedenmann et al., 2002, Proc. Natl. Acad. Sci USA 99: 11646-11651). The crystal structure of EqFP611 has been solved, and shows conservation of the 11-stranded beta-barrel structure of GFP MMDB Id: 5742 (Petersen et al., 2003, J. Biol. Chem, Aug. 8, 2003; M307896200).
Still further classes of GFP-like proteins having chromophoric and fluorescent properties have been described. One such group of coral-derived proteins, the pocilloporins, exhibit a broad range of spectral and fluorescent characteristics (Dove and Hoegh-Guldberg, 1999, PCT application WO 00/46233; Dove et al., 2001, Coral Reefs 19: 197-204). Recently, the purification and crystallization of the pocilloporin Rtms5 from the reef-building coral Montipora efflorescens has been described (Beddoe et al., 2003, Acta Cryst. D59: 597-599). Rtms5 is deep blue in color, yet is weakly fluorescent. However, it has been reported that Rtms5, as well as other chromoproteins with sequence homology to Rtms5, can be interconverted to a far-red fluorescent protein via single amino acid substitutions (Beddoe et al., 2003, supra; Bulina et al., 2002, BMC Biochem. 3: 7; Lukyanov et al., 2000, supra).
Any fluorescent protein that has a structure with a root mean square deviation of less than 5 angstroms, often less than 3, or 4 angstroms, and preferably less than 2 angstroms from the 11-stranded beta-barrel structure of MMDB Id:5742 may be used in the development of self-complementing fragments. In some cases, fluorescent proteins exist in multimeric form. For example, DsRed is tetrameric (Cotlet et al., 2001, Proc. Natl. Acad. Sci. USA 98: 14398014403). As will be appreciated by those skilled in the art, structural deviation between such multimeric fluorescent proteins and GFP (a monomer) is evaluated on the basis of the monomeric unit of the structure of the fluorescent protein.
As appreciated by one of ordinary skill in the art, such a suitable fluorescent protein or chromoprotein structure can be identified using comparison methodology well known in the art. In identifying the protein, a crucial feature in the alignment and comparison to the MMDB ID:5742 structure is the conservation of the beta-barrel structure (i.e., typically comprising 11 beta strands, but in at least one case, fewer beta strands (see, Wiedenmann et al., 2000, supra), and the topology or connection order of the secondary structural elements (see, e.g., Ormo et al. “Crystal structure of the Aequorea Victoria green fluorescent protein.” Yang et al, 1996, Science 273: 5280, 1392-5; Yang et al., 1996 Nat Biotechnol. 10:1246-51). Typically, most of the deviations between a fluorescent protein and the GFP structure are in the length(s) of the connecting strands or linkers between the crucial beta strands (see, for example, the comparison of DsRed and GFP in Yarbrough et al., 2001, Proc Natl Acad Sci USA 98:462-7). In Yarbrough et al., alignment of GFP and DsRed is shown pictorially. From the stereo diagram, it is apparent that the 11 beta-strand barrel is rigorously conserved between the two structures. The c-alpha backbones are aligned to within 1 angstrom RMSD over 169 amino acids, although the sequence identity is only 23% comparing DsRed and GFP.
In comparing structure, the two structures to be compared are aligned using algorithms familiar to those in the art, using for example the CCP4 program suite. COLLABORATIVE COMPUTATIONAL PROJECT, NUMBER 4. 1994. “The CCP4 Suite: Programs for Protein Crystallography”. Acta Cryst. D50, 760-763. In using such a program, the user inputs the PDB coordinate files of the two structures to be aligned, and the program generates output coordinates of the atoms of the aligned structures using a rigid body transformation (rotation and translation) to minimize the global differences in position of the atoms in the two structures. The output aligned coordinates for each structure can be visualized separately or as a superposition by readily-available molecular graphics programs such as RASMOL, Sayle and Milner-White, September 1995, Trends in Biochemical Science (TIBS), Vol. 20, No. 9, p. 374.), or Swiss PDB Viewer, Guex, N and Peitsch, M. C., 1996 Swiss-PdbViewer: A Fast and Easy-to-use PDB Viewer for Macintosh and PC. Protein Data Bank Quarterly Newsletter 77, pp. 7.
In considering the RMSD, the RMSD value scales with the extent of the structural alignments and this size is taken into consideration when using the RMSD as a descriptor of overall structural similarity. The issue of scaling of RMSD is typically dealt with by including blocks of amino acids that are aligned within a certain threshold. The longer the unbroken block of aligned sequence that satisfies a specified criterion, the ‘better’ aligned the structures are. In the DsRed example, 164 of the c-alpha carbons can be aligned to within 1 angstrom of the GFP. Typically, users skilled in the art will select a program that can align the two trial structures based on rigid body transformations, for example, as described in Dali et al., Journal of Molecular Biology 1993, 233, 123-138. The output of the DALI algorithm are blocks of sequence that can be superimposed between two structures using rigid body transformations. Regions with Z-scores at or above a threshold of Z=2 are reported as similar. For each such block, the overall RMSD is reported.
The RMSD of a fluorescent protein for use in the invention is within 5 angstroms for at least 80% of the sequence within the 11 beta strands. Preferably, RMSD is within 2 angstroms for at least 90% of the sequence within the 11 beta strands (the beta strands determined by visual inspection of the two aligned structures graphically drawn as superpositions, and comparison with the aligned blocks reported by DALI program output). As appreciated by one of skill in the art, the linkers between the beta strands can vary considerably, and need not be superimposable between structures.
In preferred embodiments, the fluorescent protein or chromoprotein is a mutated version of the protein or a variant of the protein that has improved folding properties or solubility in comparison to the protein. Often, such proteins can be identified, for example, using methods described in WO0123602 and other methods to select for increased folding.
For example, to obtain a fluorescent protein with increased folding properties, a “bait” or “guest” peptide that decreases the folding yield of the fluorescent protein is linked to the fluorescent protein. The guest peptide can be any peptide that, when inserted, decreases the folding yield of the fluorescent protein. A library of mutated fluorescent proteins is created. The bait peptide is inserted into the fluorescent protein and the degree of fluorescence of the protein is assayed. Those clones exhibit increased fluorescence relative to a fusion protein comprising the bait peptide and parent fluorescent protein are selected (the fluorescent intensity reflects the amount of properly folded fluorescent protein). The guest peptide may be linked to the fluorescent protein at an end, or may be inserted at an internal site.
In a particular embodiment, wild-type and mutant fluorescent proteins and chromoproteins useful in the practice of the invention may be experimentally “evolved” to produce extremely stable, “superfolding” variants. The methods described in co-pending, co-owned U.S. patent application Ser. No. 10/423,688, filed Apr. 24, 2003, hereby incorporated by reference in its entirety, may be employed for the directed evolution of GFP, DsRed, and any number of related fluorescent proteins and chromoproteins. Such superfolding variants may be split into self-complementing fragments, which fragments may be further evolved to modulate solubility characteristics of the fragments alone or when fused to test protein.
Protein Subcellular Localization Assays
The invention provides a suite of assays useful in detecting, differentiating and monitoring the subcellular location of one or more proteins in living cells, detecting proteins that interact in defined subcellular compartments, tracking the transport of proteins through and out of the cell, identifying cell surface expression, monitoring and quantifying protein secretion, and screening for mediators of localization, transport and/or secretion. These assays may also be used in combination with directed evolution strategies, and scaled to high-throughput screening of protein variants with modified subcellular localization characteristics.
In one illustrative embodiment, a test protein or group of test proteins may be screened for localization to a particular subcellular compartment or element, including without limitation the nucleus, cytoplasm, plasma membrane, endoplasmic reticulum, golgi apparatus, filaments such as actin and tubulin filaments, endosomes, peroxisomes and mitochondria. Briefly, a polynucleotide construct encoding a fusion of the test protein and a microdomain of a fluorescent protein (i.e., one or more beta-strands of the fluorescent protein, for example GFP s11) is expressed in cells containing a complementary assay fragment of the fluorescent protein that has been localized to the subcellular compartment of interest. The complementary assay fragment is functionalized to contain a localization signal sequence capable or directing the fragment into the desired subcellular compartment or element. In cases where cytoplasm expression of the test protein is to be assayed, the assay fragment is not functionalized with a particular sequence. The assay fragment may be expressed in the cell or transfected into the cell.
The expressed protein-microdomain tag fusion will only be able to complement with the assay fragment if it is able to gain access to the same subcellular compartment the assay fragment has been directed to. Thus, for example, if test protein X contains an endogenous mitochondrial localization signal, a fusion protein X-GFPs11 would be localized to the mitochondria. An assay fragment localized to the mitochondria will be available to self-complement and generate fluorescence in mitochondria, which can then be visualized using fluorescent microscopy. The assay may be used to identify proteins that localize to a particular subcellular compartment or structure and to identify novel localization signals.
In another illustrative embodiment, a test protein known to localize to the nucleus is generated as a fusion protein with a single beta-strand microdomain of a fluorescent protein (e.g., GFP s11). A complementary “assay” fragment of the fluorescent protein (i.e., GFP s1-10) is generated with a fused nuclear localization tag enabling the assay fragment to be expressed in or otherwise localized to the nucleus. Expressing the test protein-tag fusion in a cell or otherwise providing it to a cell containing the nuclear-localized assay fragment brings the two complementary fragments into proximity resulting in self-complementation and chromophore formation visualized by fluorescence. The assay may be used to screen for agents that interfere with the localization of the test protein to a particular subcellular compartment.
In some applications, the test protein-tag fragment fusion may also be functionalized to be co-localized with the assay fragment, such as where the effect of a drug on localization is being evaluated.
For cytoplasmic localization assays, the test protein is expressed in fusion with a non-perturbing tag fragment, i.e., GFP s11, or may be sandwiched in-frame between microdomains, i.e., between GFP s10 and s11. Optionally, polypeptide linkers may be used in such fusion constructs. The assay fragment, i.e., GFP s1-10 or GFP s1-9, respectively, may be expressed separately or constitutively on a plasmid. When the tagged test protein and assay fragment co-localize in the cell, complementation of the two split GFP fragments occurs, producing a fluorescent signal (FIG. 3). The intensity of the fluorescence is proportional to the number of non aggregated soluble test protein-tag fragment fusion proteins (see U.S. application Ser. No. 10/973,693, supra). In addition to co-expressing the split fragments in the cell, the assay fragment may be transected into the cell using chemical transfection methodologies known in the art.
For detecting subcellular localization to cellular elements other than the cytoplasm, it may be desirable in some applications to have expression of the test protein either precede or lag the expression or transfection of the assay fragment, in order to eliminate non-specific fluorescence resulting from transient localization of either fragment in the course of processing or transport to the element of interest. In some applications, it may be desirable to visualize protein transport through the cell over a time course, and in such applications, the test protein-tag and assay fragments may be co-expressed, from one or more constructs, and optionally under the control of individually inducible promoter systems.
Thus, in one embodiment, the functionalized assay fragment is pre-localized to the compartment of interest (e.g., GFP s1-10). This may be achieved by inducing the expression of a polynucleotide encoding the functionalized assay fragment, terminating induction, and then expressing the test protein-tag fragment fusion (e.g., X-GFP s11) through a separately inducible system. Complementation between the pre-localized assay fragment and the expressed test protein-tag fusion results in fluorescence in the specialized cell compartment (see FIG. 4, mitochondrial assay).
In a related embodiment, the cells used to conduct the assay are engineered to contain a plurality of complementary assay fragments, each of which is localized to a different subcellular compartment and designed or selected to produce different color fluorescence upon complementation with the tag. Thus, the color of the fluorescence generated when self-complementation occurs correlates with and localizes to a particular subcellular compartment or structure. Such an assay may be used to screen proteins for their subcellular localization profiles at fixed time points or in real time and to visualize protein trafficking dynamically.
For example, to visualize a test protein's transport and localization from the ER to the Golgi, two assay fragments are used, one functionalized with an ER localization signal and selected to produce cyan fluorescence upon complementation with a test protein-tag fragment fusion present in the ER, and the other functionalized with a Golgi localization signal and selected to produce yellow fluorescence upon complementation with a test protein-tag fragment fusion present in the Golgi. A third assay fragment, for example, may be functionalized with an endosomal localization signal and selected to produce green fluorescence upon complementation with a test protein-tag fragment fusion located in endosomes. A fourth assay fragment selected to produce red fluorescence could be added to the extracellular media, in excess, in order to capture test protein-tag fusions that have been secreted by the cell. Thus, this illustrative combination of fragments and colors could be used to monitor the secretion pathway of a test protein.
Similarly, the secretion assay illustrated above may be used to screen for agents that inhibit or otherwise modulate protein secretion, by adding agent(s) to the cells and observing changes in trafficking and/or secretion yields. Thus, for example, the assay fragment may be targeted to the Golgi to evaluate changes to the secretion pathway of a test protein in the presence of a drug. If a test protein is destined for secretion or export, then complementation between the test protein-tag fragment fusion and the assay fragment will occur in the Golgi, and Golgi vesicles would be visualized as fluorescent. Conversely, the absence of fluorescence provides and indication that the test protein's secretion pathway is altered by the drug.
In a related embodiment, the secretion assay enables the quantification of secreted protein yield, by comparing the fluorescence observed in the extracellular environment (e.g., growth media) with a calibration curve obtained with a soluble control protein and the same “extracellular” assay fragment. In one embodiment of a protein secretion quantitative assay, the test protein is expressed in fusion with the tag fragment (i.e., GFP s11) for a time sufficient to permit secretion of the fusion if secreted. Cells are then pelleted from growth media and an excess of a complementary assay fragment is added to the supernatant. Fluorescence is then measured and used to determine secreted protein quantity.
Secreted proteins identified as above may also be purified by including a modification to one of the split-fragments that can be used as an affinity tag. Typically, this will comprise a sequence of amino acid residues that functionalize the fragment to bind to a substrate that can be isolated using standard purification technologies. In one embodiment, a fragment is functionalized to bind to glass beads, using chemistries well known and commercially available (e.g., Molecular Probes Inc.). Alternatively, the fragment is modified to incorporate histidine residues in order to functionalize the fragment to bind to metal affinity resin beads. In a specific embodiment, a GFP s11 tag fragment, engineered so that all outside pointing residues in the β-strand are replaced with histidine residues, is used (see, U.S. application Ser. No. 10/973,693, supra). This HIS-tag fragment is non-perturbing to test proteins fused therewith, and is capable of detecting soluble protein upon complementation with a GFP s1-10 assay fragment. The HIS-tag fragment can be used to purify secreted proteins from growth media using standard cobalt bead columns, and enables the quantification of soluble and insoluble protein as well as the purification and elution of protein to 95% purity without the need for any another purification tag system.
In addition to screening for protein secretion, cell surface expression of a protein of interest may be assayed. Briefly, test protein-tag fragment fusions are expressed in the cell. The complementary assay fragment my then be added to the surface of the cells (by adding to the growth media). If the test protein-tag fragment fusion is expressed on the cell surface, complementation with the assay fragment occurs at the cell surface, effectively staining the cell surface with the reconstituted fluorescent protein. In such applications, the use of a flexible linker polypeptide, interspersed in-frame between the protein of interest and the tag fragment may provide additional flexibility and accessibility of the tag fragment to its complementary assay fragment. Additionally, it may be desirable to test both orientations of the test protein-tag fragment fusion to take account of potential membrane spanning segments which could obscure the tag fragment in some cases (i.e., x-s11 and s11-s).
Multicolor labeling strategies, as above, may also be combined with fluorescence-activated cell sorting (FACS) in order to conveniently select and isolate cells displaying a particular fluorescence. Thus, for example, if a library of protein random mutants is being screened for any which localize to the nucleus or the mitochondria, multicolored assay fragments functionalized to localize to those organelles will permit FACS differential sorting of mutants localized to one or the other organelle.
Another aspect of the invention relates to assays for timing protein localization. Since reconstituted split GFP s11+s1-10 and GFP s1-10 are visually and intrinsically two distinct entities, it may be possible to broaden the detection mode by using a multicolor version of the GFP s1-10 assay fragment. This strategy would enable differential detection of older and newly synthesized molecules, providing a useful tool for studying mechanisms of assembly of dynamic structures composed of a single family of proteins. One advantage of the split-fluorescent protein systems utilized in the present invention is that once self-complementation occurs, the reconstituted fluorescent protein is very stable, and dissociation of the fragments unlikely under physiological conditions.
In one illustrative embodiment, stable cell lines expressing the target protein X in fusion with the non perturbing short GFP s 1 tag fragment under a constitutive promoter are selected (G418, resistance for example). At desired times, an excess of the complementary assay fragment is be added by chemical transfection methods, such as the ChariotTM reagent (Morris et al., 2001, A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nature Biotechnol. 19: 1173-1176), which is capable of directly transfecting a protein into the cytoplasm of a mammalian cell. In order to study transiently the expression of the target protein, the assay fragment may contain a C-terminal destabilized tag, which can be degraded by intracellular tail-specific proteases (see further below). The tag may be adjusted to the cell type for efficient degradation (Triccas, Pinto et al. 2002).
The newly synthesized GFP s11 tagged molecules would be detected by complementation between the short and large split subunits (FIG. 5, A). The complementation would proceed until the GFP s1-10 destabilized assay fragment is degraded. Once degraded, the cells are incubated in growth media for several hours and the procedure repeated with another destabilized GFP s1-10 variant producing a different color upon complementation with GFP s11, for example red (FIG. 5, B). After several assay fragment transfection cycles, superimposition of the different images, taken for each of the excitation/emission wavelengths characteristic of the assay fragments used, would enable localization of the older synthesized protein molecules from the newer synthesized ones (FIG. 5, C).
Various approaches may be used to limit the lifetime of the individual fluorescent protein fragments used in such subcellular timing assays. Briefly, various polypeptide tags may be applied to the test protein-tag fragment in order to limit the time that an uncomplemented fragment survives. Such tags are known, and include, for example, the ubiquination sequence, the PEST sequence and mouse ornithine carboxylase. These polypeptide tags destabilize the proteins to which that are attached, marking them for degradation. Once split-fluorescent protein fragments self-complement, the reconstituted fluorescent protein is stable. Thus, such tags may be used to quickly eliminate any un-complemented fragments, from the cell entirely or in certain components of the cell (i.e., cytoplasm).
Yet another aspect of the invention relates to assays used to screen for agents that modulate protein localization. In one embodiment, a test protein-tag fragment fusion is transfected into a cell, and an agent (drug) of interest is added to the cell. Complementary assay fragments are functionalized to be directed to different subcellular compartments and result in different fluorescent colors upon complementation. The assay fragments are expressed in or transfected into the cell following the addition of the drug. Confocal microscopy is then used to examine the localization of the test protein. Indeed after complementation, the changes in fluorescence emission after addition of the drug may also be visualized, so that changes in protein localization, due to the drug, may be observed. The absence of fluorescence provides an indication of a direct effect on the protein's transport. Similarly, the modulating influence of any environmental stimulus, exogenous protein, or gene may be studied using this assay.
In yet another aspect of the invention, assays are provided for measuring the activation or inhibition of target protein expression in response to an effector, such as a transcriptional or translational activator or inhibitor. In one illustrative embodiment, the protein of interest X is cloned in fusion with a fluorescent protein tag fragment (i.e., X-GFP s11), and is expressed constitutively in a cell. The assay fragment (i.e., GFP s1-10) is subsequently transfected into the cell, and the fluorescence upon complementation defined as baseline fluorescence without the effector (Fo). After stabilization of the fluorescence level, indicating the saturation of GFP s1-10 molecules by GFP s11 tagged protein, the effector would be added to the cell or expressed in the cell. A pool of GFP s1-10 assay fragments is transfected again into the cell and the fluorescence level measured again (F1). The ratio F1/Fo provides a measure of the activation or repression of a gene under specific conditions. The assay fragment may be functionalized with localization signals or not, depending upon the nature of the interrogation.
The invention may also enable the detection of a protein that interacts with another protein in a particular subcellular compartment. Thus, for example a protein of interest is expressed in fusion with a GFP s11 tag such that it becomes localized to the subcellular compartment of interest. The localization may be a result of the protein's native localization signals or the result of a localization functionality engineered into the tag fusion. Test proteins are expressed in fusion with a GFP s10 tag. The complementary assay fragment (in this case, GFP s1-9), functionalized to transport to the subcellular compartment of interest, is expressed in the cell or transfected into the cell. Fluorescence detected in the cellular compartment of interest indicates that the three fragments co-localized and self-complemented, thus indicating that the test protein localizes to the compartment of interest and binds to the protein of interest in that compartment. This system may be used to study the effects of drugs on the interaction of proteins in particular cellular compartments. Similarly, the system may be employed to screen libraries of mutant proteins X which display modulated interactions with protein Y in a distinct cellular compartment, and to screen for protein X variants capable of overcoming the interfering influence of a drug on the interaction between X and Y in a distinct cellular compartment.
The invention also provides an improved method for screening to cellular co-expression as a means of identifying uncharacterized promoters. Briefly, an exemplary assay comprises two proteins tagged respectively with GFP s10 and GFP s11 under the control of (1) a known promoter and (2) a random or uncharacterized promoter. The complementary assay fragment GFP s1-9 is functionalized to be directed to the desired subcellular location in the cell. If simultaneous expression occurs, then complementation of the GFP s10 and s11 fusions with the GFP s1-9 assay fragment will produce fluorescence. The level of expression of the unknown promoter may be determined by complementation of the GFP s11 tagged protein with GFP s1-10. The unknown promoter might be a library of promoters for which expression levels are screened in response to a particular stimulus.
Subcellular Localization Signals
Various subcellular localization signal sequences or tags are known and/or commercially available. These tags are used to direct split-fluorescent protein fragments to particular cellular components or outside of the cell. Mammalian localization sequences capable of targeting proteins to the nucleus, cytoplasm, plasma membrane, endoplasmic reticulum, golgi apparatus, actin and tubulin filaments, endosomes, peroxisomes and mitochondria are known.
Subcellular localization signals require a specific orientation, N or C terminal to the protein to which the signal is attached. For example, the nuclear localization signal (NLS) of the simian virus 40 large T-antigen must be oriented at the C-terminus. Thus, where the test protein-tag fragment is to be localized to the nucleus, a fusion <test protein-tag fragment-NLS> or <tag fragment-test protein-NLS> (or constructs encoding tem) may be used, the former orientation being generally preferred to avoid potential perturbation of test protein by the tag fragment. Similarly, if the assay fragment is to be directed to the nucleus, the fusion <assay fragment-NLS> (or a construct encoding it) may be used.
Table 1, infra, provides example mammalian cell nuclear, Golgi, mitochondrial, and ER localization tags, together with orientation information. Table 2, infra, provides the signal sequences themselves along with the polynucleotide coding sequences. Other localization signal sequences are known and may be employed in the practice of the assays of the invention.







TABLE 1







MAMMALIAN SUBCELLULOCALIZATION TAGS













Position in fusion




Localization tag
Localization signal
protein
Function
References





Nucleus
nuclear localization signal
C-terminus
For localized
(Kalderon, Roberts et



(NLS) of the simian virus

expression in the
al. 1984)



40 large T-antigen

nucleus of mammalian
(Lanford, Kanda et al.





cells. It allows the
1986)





visualization of the





nucleus in living and





fixed cells using





fluorescence





microscopy.


Golgi
sequence encoding the N-
N-terminus
This region of human
(Watzele and Berger



terminal 81 amino acids of

beta 1,4-GT contains
1990)



human beta 1,4-

the membrane-
(Yamaguchi and



galactosyltransferase (GT)

anchoring signal
Fukuda 1995; Llopis,





peptide that targets
McCaffery et al. 1998)





the fusion protein to





the trans-medial





region of the Golgi





apparatus


Mitochondria
mitochondrial targeting
N-terminus
designed for labeling
(Rizzuto, Nakase et



sequence derived from the

of mitochondria
al. 1989; Rizzuto,



precursor of subunit VIII of


Brini et al. 1995)



human cytochrome C



oxidase


Endoplasmic reticulum
(ER) targeting sequence of
N-terminus
for labeling of the
(Munro and Pelham


(ER)
calreticulin

endoplasmic reticulum
1987; Fliegel, Burns





in mammalian cells
et al. 1989)
















TABLE 2







SUBCELLULAR LOCALIZATION SIGNAL SEQUENCES








Localization
Sequence





Nucleus
C-terminus (28 AA)


nuclear
S K K E E K G R S K K E E K G R S K K E E K G R I H R I * [SEQ ID NO:37]


localization signal
TCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGG


(NLS) of the simian
ATCCACCGGATCTAG [SEQ ID NO:38]


virus 40 large T-


antigen


 


Golgi
N-terminus (89 AA)


the N-terminal 81
M R L R E P L L S G S A A M P G A S L Q R A C R L L V A V C A L H L G V


amino acids of
T L V Y Y L A G R D L S R L P Q L V G V S T P L Q G G S N S A A A I G Q


human beta 1,4-
S S G E L R T G G A K D P P V A T [SEQ ID NO:39]


galactosyltrans-
ATGAGGCTTCGGGAGCCGCTCCTGAGCGGCAGCGCCGCGATGCCAGGCGCGTCCCTACAGCGGGCCTGCCGC


ferase (GT)
CTGCTCGTGGCCGTCTGCGCTCTGCACCTTGGCGTCACCCTCGTTTACTACCTGGCTGGCCGCGACCTGAGC



CGCCTGCCCCAACTGGTCGGAGTCTCCACACCGCTGCAGGGCGGCTCGAACAGTGCCGCCGCCATCGGGCAG



TCCTCCGGGGAGCTCCGGACCGGAGGGGCCAAGGATCCACCGGTCGCCACC [SEQ ID NO:40]


 


Mitochondria
N-terminus (36 AA)


targeting sequence
M S V L T P L L L R G L T G S A R R L P V P R A K I H S L G D P P V A T


derived from the
[SEQ ID NO:41]


precursor of sub-
ATGTCCGTCCTGACGCCGCTGCTGCTGCGGGGCTTGACAGGCTCGGCCCGGCGGCTCCCAGTGCCGCGCGCC


unit VIII of human
AAGATCCATTCGTTGGGGGATCCACCGGTCGCCACC [SEQ ID NO:42]


cytochrome C


oxidase


 


ER
N-terminus (18 AA)


targeting sequence
M L L S V P L L L G L L G L A V A V [SEQ ID NO:43]


of calreticulin
ATGCTGCTATCCGTGCCGTTGCTGCTCGGCCTCCTCGGCCTGGCCGTCGCCGTG



[SEQ ID NO:44]









Applications in Prokaryotic and Eukaryotic Cell Culture

The split-fluorescent and split-chromophoric protein systems of the invention may be applied to assays in virtually any cell type, including without limitation bacterial cells (e.g., E. coli) and mammalian cells (e.g., CHO cells). One limitation is that expression of GFP and GFP-like proteins is compromised in highly acidic environments (i.e., pH=4.0 or less). Likewise, complementation rates are generally inefficient under conditions of pH of 6.5 or lower (see U.S. application Ser. No. 10/973,693, supra).
As will be appreciated by those skilled in the art, the vectors used to express the tag and/or assay fragments must be compatible with the host cell in which the vectors are to reside. Similarly, various promoter systems are available and should be selected for compatibility with cell type, strain, etc. Codon optimization techniques may be employed to adapt sequences for use in other cells, as is well known.
When using mammalian cells for the subcellular localization assays of the invention, an alternative to codon optimization is the use of chemical transfection reagents, such as the recently described “chariot” system (Morris et al., 2001, A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nature Biotechnol. 19: 1173-1176). The ChariotTM reagent may be used to directly transfect a protein into the cytoplasm of a mammalian cell. Thus, this approach would be useful for an in vivo protein detection assay, wherein the assay fragment may be introduced into the cell, either before or after expression of the genetically-encoded test protein-tag fragment fusion by the cell.
Applications to Determining Membrane Protein Topology
The split-fluorescent and split-chromophoric protein systems of the invention may be applied to assays to dissect membrane protein topology. For example, GFP s11 can be fused to a test membrane protein (N-terminus, C-terminus, or internally), and the fusion protein is transiently expressed within a cell or cellular compartment. The protein becomes embedded or anchored within a target membrane leaf. For illustration, assume that the membrane has an internally-facing side (to the interior of the cell compartment) and an external side (to the exterior of the cell compartment). Next, the assay fragment GFP 1-10 is expressed or added using a protein transfection reagent, and is directed to the interior side of the membrane using a localization tag, for example. If the test protein is oriented with the tag directed to the interior of the membrane, complementation occurs and is detected by fluorescence. If the tag is oriented to the exterior of the compartment, complementation does not occur. Simultaneous detection of more than one possible localization event can be performed. A yellow GFP 1-10 containing T203Y can be directed to the outside of the membrane, using localization tags, for example; while the conventional “green” GFP 1-10 containing T203 is directed to the interior, using localization tags. Yellow fluorescence indicates the tag is localized to the exterior, while green indicates localization to the interior. The order of expression of the tagged protein and assay fragments can be reversed if desired to increase signal-to-noise and improve specificity. For example, the assay fragment(s) could be transiently-expressed, followed by the tagged test protein.
Methods for Isolating Improved Protein Variants
The protein subcellular localization assays described supra may be used in combination with directed evolution strategies aimed at isolating protein variants having improved or otherwise modulated characteristics relative to a parent, un-evolved protein. For example, as described infra, variants of a protein X which are able to interact with and bind with protein Y in a distinct cellular compartment may be screened and isolated using a three fragment split-fluorescent protein system.
Any method known in the art for generating a library of mutated protein variants may be used to generate candidate test proteins which may be expressed as fusions with a tag fragment. The target protein or polypeptide is usually mutated by mutating the nucleic acid. Techniques for mutagenizing are well known in the art. These include, but are not limited to, such techniques as error-prone PCR, chemical mutagenesis, and cassette mutagenesis. Alternatively, mutator strains of host cells may be employed to add mutational frequency (Greener and Callahan (1995) Strategies in Mol. Biol. 7: 32). For example, error-prone PCR (see, e.g., Ausubel, supra) uses low-fidelity polymerization conditions to introduce a low level of point mutations randomly over a long sequence. Other mutagenesis methods include, for example, recombination (WO98/42727); oligonucleotide-directed mutagenesis (see, e.g., the review in Smith, Ann. Rev. Genet. 19: 423-462 (1985); Botstein and Shortle, Science 229: 1193-1201 (1985); Carter, Biochem. J. 237: 1-7 (1986); Kunkel, “The efficiency of oligonucleotide directed mutagenesis” in Nucleic acids & Molecular Biology, Eckstein and Lilley, eds., Springer Verlag, Berlin (1987), Methods in Enzymol. 100: 468-500 (1983), and Methods in Enzymol. 154: 329-350 (1987)); phosphothioate-modified DNA mutagenesis (Taylor et al., Nucl. Acids Res. 13: 8749-8764 (1985); Taylor et al., Nucl. Acids Res. 13: 8765-8787 (1985); Nakamaye and Eckstein, Nucl. Acids Res. 14: 9679-9698 (1986); Sayers et al., Nucl. Acids Res. 16:791-802 (1988); Sayers et al., Nucl. Acids Res. 16: 803-814 (1988)), mutagenesis using uracil-containing templates (Kunkel, Proc. Nat'l. Acad. Sci. USA 82: 488-492 (1985) and Kunkel et al., Methods in Enzymol. 154:367-382, 1987); mutagenesis using gapped duplex DNA (Kramer et al., Nucl. Acids Res. 12: 9441-9456 (1984); Kramer and Fritz, Methods in Enzymol. 154:350-367 (1987); Kramer et al., Nucl. Acids Res. 16: 7207 (1988)); and Fritz et al., Nucl. Acids Res. 16: 6987-6999 (1988)). Additional methods include point mismatch repair (Kramer et al., Cell 38: 879-887 (1984)), mutagenesis using repair-deficient host strains (Carter et al., Nucl. Acids Res. 13: 4431-4443 (1985); Carter, Methods in Enzymol. 154: 382-403 (1987)), deletion mutagenesis (Eghtedarzadeh and Henikoff, Nucl. Acids Res. 14: 5115 (1986)), restriction-selection and restriction-purification (Wells et al., Phil. Trans. R. Soc. Lond. A 317: 415-423 (1986)), mutagenesis by total gene synthesis (Nambiar et al., Science 223: 1299-1301 (1984); Sakamar and Khorana, Nucl. Acids Res. 14: 6361-6372 (1988); Wells et al., Gene 34:315-323 (1985); and Grundstrom et al., Nucl. Acids Res. 13: 3305-3316 (1985). Kits for mutagenesis are commercially available (e.g., Bio-Rad, Amersham International). More recent approaches include codon-based mutagenesis, in which entire codons are replaced, thereby increasing the diversity of mutants generated, as exemplified by the RID method described in Murakami et al., 2002, Nature Biotechnology, 20: 76-81.
In a bacterial expression system, clones expressing variants may be rapidly screened for solubility using the above-described in vivo or in vitro assays. Thus, in an in vivo embodiment, a library of clones is generated in E. coli, each clone harboring an expressible construct encoding an individual variant protein fused to the tag fragment, under the control of a first and independently inducible promoter. The cells may concurrently harbor an expressible construct encoding the complementary assay fragment, under the control of a second and separately inducible promoter, or the assay fragment polypeptide itself (introduced by protein transfection methods such as described in Morris et al., 2001, supra)
In one in vivo embodiment, cells are induced to express the tag fragment-protein variant fusion, followed by expression of the complementary fragment in the cells. In most preferred embodiments, expression of the fusion is repressed or shut-down for a time sufficient to permit aggregation of insoluble fusion (i.e., 1 h), followed by the induction of complementary fragment expression. In a variation of this approach, the cells only harbor the fusion constructs, preferably under the control of an inducible/repressible promoter, and the complementary fragment is introduced by protein transfection methodologies.
Various in vitro embodiments are possible. Generally, these comprise the expression of the variant protein-tag fragment fusions in, for example, E. coli, followed by cell lysis and reaction with the complementary assay fragment polypeptide. See U.S. application Ser. No. 10/973,693, supra.
Kits
Another aspect of the invention provides kits useful in conducting the various assays described, supra. Kits of the invention may facilitate the use of split-fluorescent and split-chromophoric systems of the invention for the subcellular localization assays described herein. Various materials and reagents for practicing the assays of the invention may be provided. Kits may contain reagents including, without limitation, polypeptides or polynucleotides, cell transformation and transfection reagents, reagents and materials for purifying polypeptides, protein denaturing and refolding reagents, as well as other solutions or buffers useful in carrying out the assays and other methods of the invention. Kits may also include control samples, materials useful in calibrating the assays of the invention, and containers, tubes, microtiter plates and the like in which assay reactions may be conducted. Kits may be packaged in containers, which may comprise compartments for receiving the contents of the kits, instructions for conducting the assays, etc.
For example, kits may provide one or more split-fluorescent protein fragments of the invention, one or more polynucleotide vectors encoding one or more fluorescent protein fragments, cell strains suitable for propagating the vector, cells pretransformed or stably transfected with constructs encoding one or more fluorescent protein fragments, and reagents for purification of expressed fusion proteins.
EXAMPLES
Example 1
Complementation of Split GFP in the Cytoplasm—Detection of Cytoplasmic Proteins
Expression of Fluorescent Tagged Proteins:
A test protein, in this example, the soluble p. aerophilum sulfite reductase gamma subunit (SR), is tagged with a single beta-strand microdomain of a fluorescence protein, i.e. GFP s11 opt, and a complementary “assay” fragment of this fluorescent protein (i.e. GFP s1-10) is expressed from N-6HIS pET 28 vectors (Novagen, Madison, Wis.). 500 ml cultures of BL21 (DE3) expressing each construct are grown to OD600  ̃0.5, and induced with 1 mM IPTG for 4 h at 37° C. The culture pellets are resuspended in 10 ml TNG and sonicated. The soluble fractions are loaded onto Talon resin purification beads (TALON, Clontech, Palo Alto, Calif.). After two washes with excess TNG buffer and one wash in TNG supplemented with 5 mM imidazole, the protein is eluted with 150 mM imidazole in TNG buffer. Proteins are dialyzed in PBS buffer (mMNaCl, mMKCl, mMNa2HPO4, mMKH2PO4), quantified using Bradford Biorad protein-assay reagent (Biorad, Hercules, Calif.) and diluted to a final concentration of 1 mg/ml.
Protein Transfection in Mammalian Cells:
Hela cells (Human epithelial cells from a fatal cervical carcinoma transformed by human papillomavirus 18 (HPV18) (Henrietta Lacks, 1951) are grown at 37° C. in a 5% CO2 humidified atmosphere in Dulbecco's modified Eagle's medium (DMEM) containing 4.5 g/l glucose supplemented with 10% fetal bovine serum and 10 mM glutamine.
In a 4-well Lab-Tek chamber slide (Nalge Nunc. Int., Rochester, N.Y.), 5.0×104 cells per well are seeded in 500 μl of complete growth medium. The cells are incubated at 37° C. in a humidified atmosphere containing 5% CO2 until the cells were 50-70% confluent.
The purified proteins are diluted into 20 μl of PBS for each transfection reaction to obtain 1 μg of protein per transfection reaction. In separate tubes, one for each transfection reaction, 2 μl of Chariot reagent (Ative Motif, Carlsbad, Calif.) is diluted into 20 μl of sterile H2O. The 20 μl macromolecule dilution is mixed with the 20 μl Chariot dilution, and then incubated at room temperature for 30 minutes to allow the Chariot-macromolecule complex to form.
In the chamber slide, the medium is aspirated from the cells to be transfected, and cells are washed with PBS. The cells are then overlaid with the 40 μl Chariot-macromolecule complex and 160 μl of serum-free media added to the overlay to achieve the Final Transfection volume of 200 μl for each well.
The transfection reaction is incubated at 37° C. in a humidified atmosphere containing 5% CO2 for one hour. 400 μl of complete growth medium is added to the cells to continue incubation at 37° C. in a humidified atmosphere containing 5% CO2 for 1 to 2 hours. The media is removed from the chamber and cells are washed with PBS before mounting with a cover slip. Cells may be alternatively fixed with 2% formaldehyde to cross link proteins, washed 5 min in 25 mM glycine in PBS to neutralize the formaldehyde, and then membranes are permeabilized in 0.2% Triton X-100 in PBS.
Complementation assays in the cell requires two successive transfections, in one example the s11 tagged protein is transfected first followed by the complementary fragment GFP 1-10; in a second example the 1-10 fragment is transfected first, followed by SR-s11 protein. Complementation of the two fragments results in fluorescence in the cytoplasm or the subcellular targeted compartment.
Example 2
Complementation of Split GFP in Specialized Compartments
Cloning of Localization Sequences in Fusion with SR-s11 and GFP1-10
If both fragments contains a sequence that targets the gene of interest in a specialized compartment, then the two tagged split-GFP fragments will be targeted to this particular location and will be able to complement in the compartment.
Various subcellular localization signal sequences or tags are known and/or commercially available. These tags are used to direct split-fluorescent protein fragments to particular cellular components or outside of the cell. Mammalian localization sequences capable of targeting proteins to the nucleus, cytoplasm, plasma membrane, endoplasmic reticulum, golgi apparatus, actin and tubulin filaments, endosomes, peroxisomes and mitochondria are known.
Detailed protocols for localization in the nucleus, mitochondria and endoplasmic reticulum follow.
Localization in mitochondria: The mitochondrial targeting sequence derived from the precursor of subunit VIII of human cytochrome C oxidase was cloned in N-terminus of both SR-s11 and GFP 1-10 OPT to yield the constructs MTS-SR-s11 or MTS-1-10opt. The mitochondrial targeting sequence (MTS) was amplified from the commercially available plasmid pECFP_Mito vector (BD Biosciences Clontech, Palo Alto, Calif.) using specific primers









[SEQ ID NO:45]



TAAGAAGGAGATATAATGGTCCTGACGCCGCTGCTGCTG



and



 



[SEQ ID NO:46]



CAGCAGCGGCGTCAGGACCATTATATCTCCTTCTTAAAG






which tails the MTS sequence to a pET translation initiation sequence, and downstream primers










[SEQ ID NO:47]



GGCGACCGGTGGGTCCCCCAACGAATGGATCTT



and



 



[SEQ ID NO:48]



CTATATCATATGAGAACCGCCACCGGTGGCGACCGGTGGGTC






that include a GGGS [SEQ ID NO: 49] linker between the MTS sequence and the protein of interest (SR-s11 fusion or 1-10opt). The entire cassette was digested with SphI/NdeI and cloned in the receiving vector pET SR-s11_C6his vector. The MTS-GFP1-10 construct was created by cloning 1-10opt in place of SR-s11 protein, using NdeI/KpnI restriction sites. MTS tagged proteins are expressed and transfected as described supra in Example 1.

For nucleotide and amino acid sequences of MTS-SR-s11, see SEQ ID NOS: 53-54.
For nucleotide and amino acid sequences of MTS-GFP 1-10opt, see SEQ ID NOS: 61-62).
Nuclear localization: The nuclear localization signal (NLS) of the simian virus 40 large T-antigen was cloned in C-terminus of both target proteins expressed in fusion with the s11 tag at the N-terminus, and GFP1-10opt. The NLS sequence was amplified from the commercially available vector pDsRed_Nuc (BD Biosciences Clontech, Palo Alto, Calif.) using forward specific primers









[SEQ ID NO:50]



GGCGGTTCTTCCAAAAAAGAAGAGAAAGGTAGA



and



 



[SEQ ID NO:51]



GATATAGGATCCGGTGGCGGTTCTTCCAAAAAAGAA,






which include a BamHI cloning site, and reverse specific primers










[SEQ ID NO:52]



TTAGATCCGGTGTATCCTACCTTTCTCTTCTTT



and



 



[SEQ ID NO:53]



CTATATCTCGAGTTAGATCCGGTGTATCCTACC,






which silence BamHI in the NLS sequence and include an XhoI site at the 3′ end. The entire cassette is digested BamHII/XhoI and cloned in the receiving vector pET N6his-L-s11-SR- vector (see SEQ ID NOS: 65-66). The GFP1-10 NLS construct was created by cloning 1-10opt in place of s11-SR protein, using SpeI/BamHI restriction sites. NLS tagged proteins are expressed and transfected as described supra in Example 1.

For nucleotide and amino acid sequences of s11-SR-NLS, see SEQ ID NOS:67-68.
For nucleotide and amino acid sequences of GFP 1-10opt-NLS, see SEQ ID NOS: 69-70.
Endoplasmic reticulum (ER) localization: The ER localization of proteins require the fusion at the N-terminus of 18 amino-acid targeting sequence of calreticulin (CAL) and retention of the protein in the ER compartment requires the presence of a KDEL [SEQ ID NO: 54] peptide at the C-terminus of the target protein.
The CAL sequence is cloned into the N-terminus of SR-s11 and GFP1-10opt, and includes the KDEL [SEQ ID NO: 54] linker in C-terminus of both proteins.
The targeting sequence of calreticulin (CAL) is amplified from the commercially available plasmid pDsRed ER vector (BD Biosciences Clontech, Palo Alto, Calif.) using specific primers









[SEQ ID NO:55]



TAAGAAGGAGATATAATGCTGCTATCCGTGCCGTTGC



and



 



[SEQ ID NO:56]



CGGCACGGATAGCAGCATTATATCTCCTTCTTAAAG






which tails the CAL sequence to a pET translation initiation sequence, and downstream primers that include a GGGS [SEQ ID NO: 49] linker fater the CAL sequence and include a NdeI restriction site. The entire cassette is digested SphI/NdeI and cloned in the receiving vector pET SR-s11_C6his vector.

The retention sequence KDEL [SEQ ID NO: 54] was created using forward specific primers









[SEQ ID NO:57]



GATATAGGTACCGGTGGCGGTTCTCACCACCACCACCAC



and



 



[SEQ ID NO:58]



TCTCACCACCACCACCACCACGGTGGCGGTTCT






which include a linker between the target protein and the C-terminal HIS-tag, and reverse specific primers










[SEQ ID NO:59]



CAGCTCGTCCTTAGAACCGCCACCGTGGTGGTG



and



 



[SEQ ID NO:60]



CTATATCTCGAGTTACAGCTCGTCCTTAGAACCGCCACC,






which include the C-terminal KDEL [SEQ ID NO: 54] sequence. The 6HIS-KDEL stuffer was cloned using KpnI/XhoI restriction sites in the N-terminal CAL pET vector. The CAL-GFP1-10-KDEL construct was created by cloning 1-10opt in place of SR-s11 protein, using NdeI/KpnI restriction sites.

For nucleotide and amino acid sequences of CAL-SR-s11-KDEL, see SEQ ID NOS:71-72.
For nucleotide and amino acid sequences of CAL-GFP1-10opt-KDEL, see SEQ ID NOS:73-74.
Golgi
Primers specific from the Golgi localization sequence (GLS) are used to amplify the 81 amino-acid sequence from the commercially available vector pDsRed_Golgi (Clontech). The GLS cassette is cloned in N-terminus of SR-s11 and GFP 1-10opt similarly as it was done for the N-terminal Mitochondria localization sequence (See supra).
All publications, patents, and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.
The present invention is not to be limited in scope by the embodiments disclosed herein, which are intended as single illustrations of individual aspects of the invention, and any which are functionally equivalent are within the scope of the invention. Various modifications to the models and methods of the invention, in addition to those described herein, will become apparent to those skilled in the art from the foregoing description and teachings, and are similarly intended to fall within the scope of the invention. Such modifications or other embodiments can be practiced without departing from the true scope and spirit of the invention.
LITERATURE CITED


    Adams, S. R., R. E. Campbell, et al. (2002). “New biarsenical ligands and tetracysteine motifs for protein labeling in vitro and in vivo: synthesis and biological applications.” J Am Chem Soc 124(21): 6063-76.
    Arai, M., K. Maki, et al. (2003). “Testing the relationship between foldability and the early folding events of dihydrofolate reductase from Escherichia coli.” J Mol Biol 328(1): 273-88.
    Armstrong, N., A. de Lencastre, et al. (1999). “A new protein folding screen: application to the ligand binding domains of a glutamate and kainate receptor and to lysozyme and carbonic anhydrase.” Protein Sci 8(7): 1475-83.
    Baird, G. S., D. A. Zacharias, et al. (1999). “Circular permutation and receptor insertion within green fluorescent proteins.” Proc Natl Acad Sci USA 96(20): 11241-6.
    Baneyx, F. (1999). “Recombinant protein expression in Escherichia coli.” Curr Opin Biotechnol 10(5): 411-21.
    Bertens, P., W. Heijne, et al. (2003). “Studies on the C-terminus of the Cowpea mosaic virus movement protein.” Arch Virol 148(2): 265-79.
    Crameri, A., E. A. Whitehorn, et al. (1996). “Improved green fluorescent protein by molecular evolution using DNA shuffling.” Nat Biotechnol 14(3): 315-9.
    Fahnert, B., H. Lilie, et al. (2004). “Inclusion bodies: formation and utilisation.” Adv Biochem Eng Biotechnol 89: 93-142.
    Fitz-Gibbon, S., A. J. Choi, et al. (1997). “A fosmid-based genomic map and identification of 474 genes of the hyperthermophilic archaeon Pyrobaculum aerophilum.” Extremophiles 1(1): 36-51.
    Fox, J. D., R. B. Kapust, et al. (2001). “Single amino acid substitutions on the surface of Escherichia coli maltose-binding protein can have a profound impact on the solubility of fusion proteins.” Protein Sci 10(3): 622-30.
    Gegg, C. V., K. E. Bowers, et al. (1997). “Probing minimal independent folding units in dihydrofolate reductase by molecular dissection.” Protein Sci 6(9): 1885-92.
    Gerstein, M., A. Edwards, et al. (2003). “Structural genomics: current progress.” Science 299(5613): 1663.
    Goh, C. S., N. Lan, et al. (2004). “Mining the structural genomics pipeline: identification of protein properties that affect high-throughput experimental analysis.” J Mol Biol 336(1): 115-30.
    Iwakura, M. and T. Nakamura (1998). “Effects of the length of a glycine linker connecting the N— and C-termini of a circularly permuted dihydrofolate reductase.” Protein Eng 11(8): 707-13.
    Iwakura, M., T. Nakamura, et al. (2000). “Systematic circular permutation of an entire protein reveals essential folding elements.” Nat Struct Biol 7(7): 580-5.
    Jappelli, R., A. Luzzago, et al. (1992). “Loop mutations can cause a substantial conformational change in the carboxy terminus of the ferritin protein.” J Mol Biol 227(2): 532-43.
    Kelemen, B. R., T. A. Klink, et al. (1999). “Hypersensitive substrate for ribonucleases.” Nucleic Acids Res 27(18): 3696-701.
    Kim, J. S. and R. T. Raines (1993). “Ribonuclease S-peptide as a carrier in fusion proteins.” Protein Sci 2(3): 348-56.
    Knaust, R. K. and P. Nordlund (2001). “Screening for soluble expression of recombinant proteins in a 96-well format.” Anal Biochem 297(1): 79-85.
    Lopes Ferreira, N. and J. H. Alix (2002). “The DnaK chaperone is necessary for alpha-complementation of beta-galactosidase in Escherichia coli.” J Bacteriol 184(24): 7047-54.
    Lutz, R. and H. Bujard (1997). “Independent and tight regulation of transcriptional units in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements.” Nucleic Acids Res 25(6): 1203-10.
    Makrides, S. C. (1996). “Strategies for achieving high-level expression of genes in Escherichia coli.” Microbiol Rev 60(3): 512-38.
    Nixon, A. E. and S. J. Benkovic (2000). “Improvement in the efficiency of formyl transfer of a GAR transformylase hybrid enzyme.” Protein Eng 13(5): 323-7.
    Ormö, M., A. B. Cubitt, et al. (1996). “Crystal structure of the Aequorea victoria green fluorescent protein.” Science 273(5280): 1392-1395.
    Patterson, G. H., S. M. Knobel, et al. (1997). “Use of the green fluorescent protein and its mutants in quantitative fluorescence microscopy.” Biophys J 73(5): 2782-90.
    Pelletier, J. N., K. M. Arndt, et al. (1999). “An in vivo library-versus-library selection of optimized protein-protein interactions.” Nat Biotechnol 17(7): 683-90.
    Pelletier, J. N., F. X. Campbell-Valois, et al. (1998). “Oligomerization domain-directed reassembly of active dihydrofolate reductase from rationally designed fragments.” Proc Natl Acad Sci USA 95(21): 12141-6.
    Richards, F. M. and P. J. Vithayathil (1959). “The preparation of subtilisn-modified ribonuclease and the separation of the peptide and protein components.” J Biol Chem 234(6): 1459-65.
    Rossi, F. M., B. T. Blakely, et al. (2000). “Monitoring protein-protein interactions in live mammalian cells by beta-galactosidase complementation.” Methods Enzymol 328: 231-51.
    Smith, V. F. and C. R. Matthews (2001). “Testing the role of chain connectivity on the stability and structure of dihydrofolate reductase from E. coli: fragment complementation and circular permutation reveal stable, alternatively folded forms.” Protein Sci 10(1): 116-28.
    Stemmer, W. P. (1994). “DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution.” Proc Natl Acad Sci USA 91(22): 10747-51.
    Studier, F. W., A. H. Rosenberg, et al. (1990). “Use of T7 RNA polymerase to direct expression of cloned genes.” Methods Enzymol 185: 60-89.
    Tal, M., A. Silberstein, et al. (1985). “Why does Coomassie Brilliant Blue R interact differently with different proteins? A partial answer.” J Biol Chem 260(18): 9976-80.
    Terwilliger, T. C. (2004). “Structures and technology for biologists.” Nat Struct Mol Biol 11(4): 296-7.
    Tsien, R. Y. (1998). “The green fluorescent protein.” Annu Rev Biochem 67: 509-44.
    Ullmann, A., F. Jacob, et al. (1967). “Characterization by in vitro complementation of a peptide corresponding to an operator-proximal segment of the beta-galactosidase structural gene of Escherichia coli.” J Mol Biol 24(2): 339-43.
    Waldo, G. S. (2003). “Genetic screens and directed evolution for protein solubility.” Curr Opin Chem Biol 7(1): 33-8.
    Waldo, G. S. (2003). “Improving protein folding efficiency by directed evolution using the GFP folding reporter.” Methods Mol Biol 230: 343-59.
    Waldo, G. S., B. M. Standish, et al. (1999). “Rapid protein-folding assay using green fluorescent protein.” Nature Biotechnology 17(#7): 691-695.
    Wehrman, T., B. Kleaveland, et al. (2002). “Protein-protein interactions monitored in mammalian cells via complementation of beta-lactamase enzyme fragments.” Proc Natl Acad Sci USA 99(6): 3469-74.
    Welply, J. K., A. V. Fowler, et al. (1981). “beta-Galactosidase alpha-complementation. Effect of single amino acid substitutions.” J Biol Chem 256(13): 6811-6.
    Wigley, W. C., R. D. Stidham, et al. (2001). “Protein solubility and folding monitored in vivo by structural complementation of a genetic marker protein.” Nat Biotechnol 19(2): 131-6.
    Worrall, D. M. and N. H. Goss (1989). “The formation of biologically active beta-galactosidase inclusion bodies in Escherichia coli.” Aust J Biotechnol 3(1): 28-32.
    Yang, F., L. G. Moss, et al. (1996). “The molecular structure of green fluorescent protein.” Nature Biotechnology 14(10): 1246-1251.
    Yokoyama, S. (2003). “Protein expression systems for structural genomics and proteomics.” Curr Opin Chem Biol 7(1): 3943.
    Feilmeier, B. J., G. Iseminger, et al. (2000). “Green fluorescent protein functions as a reporter for protein localization in Escherichia coli.” J Bacteriol 182(14): 4068-76.
    Fliegel, L., K. Burns, et al. (1989). “Molecular cloning of the high affinity calcium-binding protein (calreticulin) of skeletal muscle sarcoplasmic reticulum.” J Biol Chem 264(36): 21522-8.
    Gaietta, G., T. J. Deerinck, et al. (2002). “Multicolor and electron microscopic imaging of connexin trafficking.” Science 296(5567): 503-7.
    Hanson, D. A. and S. F. Ziegler (2004). “Fusion of green fluorescent protein to the C-terminus of granulysin alters its intracellular localization in comparison to the native molecule.” J Negat Results Biomed 3(1): 2.
    Kalderon, D., B. L. Roberts, et al. (1984). “A short amino acid sequence able to specify nuclear location.” Cell 39(3 Pt 2): 499-509.
    Lanford, R. E., P. Kanda, et al. (1986). “Induction of nuclear transport with a synthetic peptide homologous to the SV40 T antigen transport signal.” Cell 46(4): 575-82.
    Liopis, J., J. M. McCaffery, et al. (1998). “Measurement of cytosolic, mitochondrial, and Golgi pH in single living cells with green fluorescent proteins.” Proc Natl Acad Sci USA 95(12): 6803-8.
    Morris, M. C., J. Depollier, et al. (2001). “A peptide carrier for the delivery of biologically active proteins into mammalian cells.” Nat Biotechnol 19(12): 1173-6.
    Munro, S. and H. R. Pelham (1987). “A C-terminal signal prevents secretion of luminal ER proteins.” Cell 48(5): 899-907.
    Ozawa, T., Y. Sako, et al. (2003). “A genetic approach to identifying mitochondrial proteins.” Nat Biotechnol 21(3): 287-93.
    Rizzuto, R., M. Brini, et al. (1995). “Chimeric green fluorescent protein as a tool for visualizing subcellular organelles in living cells.” Curr Biol 5(6): 635-42.
    Rizzuto, R., H. Nakase, et al. (1989). “A gene specifying subunit VIII of human cytochrome c oxidase is localized to chromosome 11 and is expressed in both muscle and non-muscle tissues.” J Biol Chem 264(18): 10595-600.
    Southward, C. M. and M. G. Surette (2002). “The dynamic microbe: green fluorescent protein brings bacteria to light.” Mol Microbiol 45(5): 1191-6.
    Tanudji, M., S. Hevi, et al. (2002). “Improperly folded green fluorescent protein is secreted via a non-classical pathway.” J Cell Sci 115(Pt 19): 3849-57.
    Triccas, J. A., R. Pinto, et al. (2002). “Destabilized green fluorescent protein for monitoring transient changes in mycobacterial gene expression.” Res Microbiol 153(6): 379-83.
    Watzele, G. and E. G. Berger (1990). “Near identity of HeLa cell galactosyltransferase with the human placental enzyme.” Nucleic Acids Res 18(23): 7174.
    Yamaguchi, N. and M. N. Fukuda (1995). “Golgi retention mechanism of beta-1,4-galactosyltransferase. Membrane-spanning domain-dependent homodimerization and association with alpha- and beta-tubulins.” J Biol Chem 270(20): 12170-6.
    Zhang, S., C. Ma, et al. (2004). “Combinatorial marking of cells and organelles with reconstituted fluorescent proteins.” Cell 119(1): 137-44.












TABLE OF SEQUENCES
















SEQ ID NO:1



GFP superfolder 1-10 nucleotide sequence:


ATGAGCAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGT


 


GATGTTAATGGGCACAAATTTTCTGTCAGAGGAGAGGGTGAAGGTGATGCTACAAACGGA


 


AAACTCACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTT


 


GTCACTACTCTGACCTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAACGG


 


CATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTC


 


AAAGATGACGGGACCTACAAGACGCGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTT


 


AATCGTATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTCGGACACAAA


 


CTCGAGTACAACTTTAACTCACACAATGTATACATCACGGCAGACAAACAAAAGAATGGA


 


ATCAAAGCTAACTTCAAAATTCGCCACAACGTTGAAGATGGTTCCGTTCAACTAGCAGAC


 


CATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTAC


 


CTGTCGACACAATCTGTCCTTTCGAAAGATCCCAACGAAAAGCTAA


 


SEQ ID NO:2


GFP super folder 1-10 amino acid sequence:


MSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLPVPWPTL


 


VTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGTYKTRAEVKFEGDTLV


 


NRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKANFKIRHNVEDGSVQLAD


 


HYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEK


 


SEQ ID NO:3


GFP 1-10 OPT nucleotide sequence:


ATGAGCAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGT


 


GATGTTAATGGGCACAAATTTTCTGTCAGAGGAGAGGGTGAAGGTGATGCTACAATCGGA


 


AAACTCACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTT


 


GTCACTACTCTGACCTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAAAGG


 


CATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTC


 


AAAGATGACGGGAAATACAAGACGCGTGCTGTAGTCAAGTTTGAAGGTGATACCCTTGTT


 


AATCGTATCGAGTTAAAGGGTACTGATTTTAAAGAAGATGGAAACATTCTCGGACACAAA


 


CTCGAGTACAACTTTAACTCACACAATGTATACATCACGGCAGACAAACAAAAGAATGGA


 


ATCAAAGCTAACTTCACAGTTCGCCACAACGTTGAAGATGGTTCCGTTCAACTAGCAGAC


 


CATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTAC


 


CTGTCGACACAAACTGTCCTTTCGAAAGATCCCAACGAAAAGGGTACCTAA


 


SEQ ID NO:4


GFP 1-10 OPT amino acid sequence:


(additional mutations vs. superfolder: N39I, T105K, E111V,


I128T, K166T, I167V, S205T)


MSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATIGKLTLKFICTTGKLPVPWPTL


 


VTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGKYKTRAVVKFEGDTLV


 


NRIELKGTDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKANFTVRHNVEDGSVQLAD


 


HYQQNTPIGDGPVLLPDNHYLSTQTVLSKDPNEKGT


 


SEQ ID NO:5


GFP 1-10 A4 nucleotide sequence:


ATGAGCAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGA


 


GATGTTAATGGGCACAAATTTTCTGTCAGAGGAGAGGGTGAAGGTGATGCTACAAACGGA


 


AAACTCACCCTTAAATTCATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACGCTT


 


GTCACTACTCTGACCTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAACAG


 


CATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATATTTC


 


AAAGATGACGGGAACTACAAGACGCGTGCTGTAGTCAAGTTTGAAGGTGATACCCTTGTT


 


AATCGTATCGAGTTAAAGGGTACTGATTTTAAAGAAGATGGAAACATTCTCGGACACAAA


 


CTCGAGTACAACTTTAACTCACACAATGTATATATCACGGCAGACAAACAAAAGAATGGA


 


ATCAAAGCTAACTTCACAATTCGCCACAACGTTGTAGATGGTTCCGTTCAACTAGCAGAC


 


CATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTAC


 


TTGTCGACACAAACTGTCCTTTCGAAAGATCCCAACGAAAAGGGTACCTAA


 


SEQ ID NO:6


GFP 1-10 A4 amino acid sequence:


(additional mutations versus Superfolder GFP: R80Q, S99Y,


T105N, E111V, I128T, K166T, E172V, S205T)


MSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLPVPWPTL


 


VTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIYFKDDGNYKTRAVVKFEGDTLV


 


NRIELKGTDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKANFTIRHNVVDGSVQLAD


 


HYQQNTPIGDGPVLLPDNHYLSTQTVLSKDPNEKGT


 


SEQ ID NO:7


GFP S11 214-238 nucleotide sequence:


AAGCGTGACCACATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACACATGGCATG


 


GATGAGCTCTACAAAGGTACCTAA


 


SEQ ID NO:8


GFP S11 214-238 amino acid sequence:


KRDHMVLLEFVTAAGITHGMDELYKGT


 


SEQ ID NO:9


GFP S11 214-230 nucleotide sequence:


AAGCGTGACCACATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACAGGTACCTAA


 


SEQ ID NO:10


GFP S11 214-230 amino acid sequence:


KRDHMVLLEFVTAAGITGT


 


SEQ ID NO:11


GFP S11 M1 nucleotide sequence:


AAGCGTGACCACATGGTCCTTCATGAGTTTGTAACTGCTGCTGGGATTACAGGTACCTAA


 


SEQ ID NO:12


GFP S11 M1 amino acid sequence:


(Additional mutation versus wt: L221H)


KRDHMVLHEFVTAAGITGT


 


SEQ ID NO:13


GFP S11 M2 nucleotide sequence:


AAGCGTGACCACATGGTCCTTCATGAGTCTGTAAATGCTGCTGGGGGTACCTAA


 


SEQ ID NO:14


GFP S11 M2 amino acid sequence:


(Additional mutations versus GFP 11 wt: L221H, F2235, T225N


AA sequence 17 residues


KRDHMVLHESVNAAGGT


 


SEQ ID NO:15


GFP S11 M3 nucleotide sequence:


CGTGACCACATGGTCCTTCATGAGTCTGTAAATGCTGCTGGGATTACATAA


 


SEQ ID NO:16


GFP S11 M3 amino acid sequence:


(Additional mutations versus GFP 11 wt: L221H, F223Y, T225N)


RDHMVLHEYVNAAGIT*


 


SEQ ID NO:17


GFP S11 H7 nucleotide sequence:


AAGCATGACCACATGCACCTTCATGAGCATGTACATGCTCATGGGGGTACCTAA


 


SEQ ID NO:18


GFP S11 H7 amino acid sequence:


(Additional mutations versus GFP 11 wt: R215H, V219H, L221H,


F223H, T225H, A227H)


KHDHMHLHEHVHAHGGT


 


SEQ ID NO:19


GFP S11 H9 nucleotide sequence:


CATGACCACATGCACCTTCATGAGCATGTACATGCTCATCACCATACCTAA


 


SEQ ID NO:20


GFP S11 H9 amino acid sequence:


(Additional mutations versus GFP 11 wt: R215H, V219H, L221H,


F223H, T225H, A227H, G228H, I229H)


HDHMHLHEHVHAHHHT


 


SEQ ID NO:21


UNIQUE GENETIC ELEMENTS FROM PTET-SPECR VECTOR


(These comprise the elements from T0 to Aatll: tet repressor


protein tetR and the Spectinomycin gene under the control


of the kanamycin promoter, and the RBS that control the ex-


pression of the tet repressor)


TTAAGACCCACTTTCACATTTAAGTTGTTTTTCTAATCCGTATATGATCAATTCAAGGCC


 


GAATAAGAAGGCTGGCTCTGCACCTTGGTGATCAAATAATTCGATAGCTTGTCGTAATAA


 


TGGCGGCATACTATCAGTAGTAGGTGTTTCCCTTTCTTCTTTAGCGACTTGATGCTCTTG


 


ATCTTCCAATACGCAACCTAAAGTAAAATGCCCCACAGCGCTGAGTGCATATAATGCATT


 


CTCTAGTGAAAAACCTTGTTGGCATAAAAAGGCTAATTGATTTTCGAGAGTTTCATACTG


 


TTTTTCTGTAGGCCGTGTACCTAAATGTACTTTTGCTCCATCGCGATGACTTAGTAAAGC


 


ACATCTAAAACTTTTAGCGTTATTACGTAAAAAATCTTGCCAGCTTTCCCCTTCTAAAGG


 


GCAAAAGTGAGTATGGTGCCTATCTAACATCTCAATGGCTAAGGCGTCGAGCAAAGCCCG


 


CTTATTTTTTACATGCCAATACAATGTAGGCTGCTCTACACCTAGCTTCTGGGCGAGTTT


 


ACGGGTTGTTAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAATGCGCTGTTAATCAC


 


TTTACTTTTATCTAATCTGGACATCATTAATGTTTATTGAGCTCTCGAACCCCAGAGTCC


 


CGCATTATTTGCCGACTACCTTGGTGATCTCGCCTTTCACGTAGTGGACAAATTCTTCCA


 


ACTGATCTGCGCGCGAGGCCAAGCGATCTTCTTCTTGTCCAAGATAAGCCTGTCTAGCTT


 


CAAGTATGACGGGCTGATACTGGGCCGGCAGGCGCTCCATTGCCCAGTCGGCAGCGACAT


 


CCTTCGGCGCGATTTTGCCGGTTACTGCGCTGTACCAAATGCGGGACAACGTAAGCACTA


 


CATTTCGCTCATCGCCAGCCCAGTCGGGCGGCGAGTTCCATAGCGTTAAGGTTTCATTTA


 


GCGCCTCAAATAGATCCTGTTCAGGAACCGGATCAAAGAGTTCCTCCGCCGCTGGACCTA


 


CCAAGGCAACGCTATGTTCTCTTGCTTTTGTCAGCAAGATAGCCAGATCAATGTCGATCG


 


TGGCTGGCTCGAAGATACCTGCAAGAATGTCATTGCGCTGCCATTCTCCAAATTGCAGTT


 


CGCGCTTAGCTGGATAACGCCACGGAATGATGTCGTCGTGCACAACAATGGTGACTTCTA


 


CAGCGCGGAGAATCTCGCTCTCTCCAGGGGAAGCCGAAGTTTCCAAAAGGTCGTTGATCA


 


AAGCTCGCCGCGTTGTTTCATCAAGCCTTACGGTCACCGTAACCAGCAAATCAATATCAC


 


TGTGTGGCTTCAGGCCGCCATCCACTGCGGAGCCGTACAAATGTACGGCCAGCAACGTCG


 


GTTCGAGATGGCGCTCGATGACGCCAACTACCTCTGATAGTTGAGTCGATACTTCGGCGA


 


TCACCGCTTCCCTCATGATGTTTAACTTTGTTTTAGGGCGACTGCCCTGCTGCGTAACAT


 


CGTTGCTGCTCCATAACATCAAACATCGACCCACGGCGTAACGCGCTTGCTGCTTGGATG


 


CCCGAGGCATAGACTGTACCCCAAAAAAACATGTCATAACAAGCCATGAAAACCGCCACT


 


GCGCCGTTACCATGCGAAACGATCCTCATCCTGTCTCTTGATCAGATCTTGATCCCCTGC


 


GCCATCAGATCCTTGGCGGCAAGAAAGCCATCCAGTTTACTTTGCAGGGCTTCCCAACCT


 


TACCAGAGGGCGCCCCAGCTGGCAATTCCGACGTC


 


SEQ ID NO:22


COMPLETE PTET-SPECR VECTOR SEQUENCE


TCGAGTCCCTATCAGTGATAGAGATTGACATCCCTATCAGTGATAGAGATACTGAGCACA


 


TCAGCAGGACGCACTGACCGAGTTCATTAAAGAGGAGAAAGATACCCATGGGCAGCAGCC


 


ATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGGTGGCGGTT


 


CTGGATCCGGAGGCACTAGTGGTGGCGGCTCAGGTACCTAACTCGAGCACCACCACCACC


 


ACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCG


 


CTGAGCAATAACTAGCATAACCTCTAGAGGCATCAAATAAAACGAAAGGCTCAGTCGAAA


 


GACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACGCTCTCCTGAGTAGGACAAAT


 


CCGCCGCCCTAGACCTAGGCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGG


 


TAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCC


 


AGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCC


 


CCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGAC


 


TATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCGCTCGTGCGCTCTCCTGTTCCGACCC


 


TGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAAT


 


GCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGC


 


ACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCA


 


ACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAG


 


CGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTA


 


GAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTG


 


GTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGC


 


AGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGT


 


CTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGACTAGCGCTTGGA


 


TTCTCACCAATAAAAAACGCCCGGCGGCAACCGAGCGTTCTGAACAAATCCAGATGGAGT


 


TCTGAGGTCATTACTGGATCTATCAACAGGAGTCCAAGCTTAAGACCCACTTTCACATTT


 


AAGTTGTTTTTCTAATCCGTATATGATCAATTCAAGGCCGAATAAGAAGGCTGGCTCTGC


 


ACCTTGGTGATCAAATAATTCGATAGCTTGTCGTAATAATGGCGGCATACTATCAGTAGT


 


AGGTGTTTCCCTTTCTTCTTTAGCGACTTGATGCTCTTGATCTTCCAATACGCAACCTAA


 


AGTAAAATGCCCCACAGCGCTGAGTGCATATAATGCATTCTCTAGTGAAAAACCTTGTTG


 


GCATAAAAAGGCTAATTGATTTTCGAGAGTTTCATACTGTTTTTCTGTAGGCCGTGTACC


 


TAAATGTACTTTTGCTCCATCGCGATGACTTAGTAAAGCACATCTAAAACTTTTAGCGTT


 


ATTACGTAAAAAATCTTGCCAGCTTTCCCCTTCTAAAGGGCAAAAGTGAGTATGGTGCCT


 


ATCTAACATCTCAATGGCTAAGGCGTCGAGCAAAGCCCGCTTATTTTTTACATGCCAATA


 


CAATGTAGGCTGCTCTACACCTAGCTTCTGGGCGAGTTTACGGGTTGTTAAACCTTCGAT


 


TCCGACCTCATTAAGCAGCTCTAATGCGCTGTTAATCACTTTACTTTTATCTAATCTGGA


 


CATCATTAATGTTTATTGAGCTCTCGAACCCCAGAGTCCCGCATTATTTGCCGACTACCT


 


TGGTGATCTCGCCTTTCACGTAGTGGACAAATTCTTCGAACTGATCTGCGCGCGAGGCCA


 


AGCGATCTTCTTCTTGTCCAAGATAAGCCTGTCTAGCTTCAAGTATGACGGGCTGATACT


 


GGGCCGGCAGGCGCTCCATTGCCCAGTCGGCAGCGACATCCTTCGGCGCGATTTTGCCGG


 


TTACTGCGCTGTACCAAATGCGGGACAACGTAAGCACTACATTTCGCTCATCGCCAGCCC


 


AGTCGGGCGGCGAGTTCCATAGCGTTAAGGTTTCATTTAGCGCCTCAAATAGATCCTGTT


 


CAGGAACCGGATCAAAGAGTTCCTCCGCCGCTGGACCTACCAAGGCAACGCTATGTTCTC


 


TTGCTTTTGTCAGCAAGATAGCCAGATCAATGTCGATCGTGGCTGGCTCGAAGATACCTG


 


CAAGAATGTCATTGCGCTGCCATTCTCCAAATTGCAGTTCGCGCTTAGCTGGATAACGCC


 


ACGGAATGATGTCGTCGTGCACAACAATGGTGACTTCTACAGCGCGGAGAATCTCGCTCT


 


CTCCAGGGGAAGCCGAAGTTTCCAAAAGGTCGTTGATCAAAGCTCGCCGCGTTGTTTCAT


 


CAAGCCTTACGGTCACCGTAACCAGCAAATCAATATCACTGTGTGGCTTCAGGCCGCCAT


 


CCACTGCGGAGCCGTACAAATGTACGGCCAGCAACGTCGGTTCGAGATGGCGCTCGATGA


 


CGCCAACTACCTCTGATAGTTGAGTCGATACTTCGGCGATCACCGCTTCCCTCATGATGT


 


TTAACTTTGTTTTAGGGCGACTGCCCTGCTGCGTAACATCGTTGCTGCTCCATAACATCA


 


AACATCGACCCACGGCGTAACGCGCTTGCTGCTTGGATGCCCGAGGCATAGACTGTACCC


 


CAAAAAAACATGTCATAACAAGCCATGAAAACCGCCACTGCGCCGTTACCATGCGAAACG


 


ATCCTCATCCTGTCTCTTGATCAGATCTTGATCCCCTGCGCCATCAGATCCTTGGCGGCA


 


AGAAAGCCATCCAGTTTACTTTGCAGGGCTTCCCAACCTTACCAGAGGGCGCCCCAGCTG


 


GCAATTCCGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTA


 


TCACGAGGCCCTTTCGTCTTCACC


 


SEQ ID NO:23


Nucleotide sequence of GFP 1-9 OPT


ATGCGCAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGT


 


GATGTTAATGGGCACAAATTTTCTGTCCGTGGAGAGGGTGAAGGTGATGCTACAAACGGA


 


AAACTCAGCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTT


 


GTCACTACTCTGACCTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAACGG


 


CATGACTTTTTCAAGAGTGTCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTC


 


AAAGATGACGGGACCTACAAGACGCGTGCTGAAGTCAAGTCTGAAGGTGATACCCTTGTT


 


AATCGTATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTCGGACACAAA


 


CTCGAGTACAACTTTAACTCACACAATGTATACATCACGGCAGACAAACAAAAGAATGGA


 


ATCAAAGCTAACTTCACAATTCGCCACAACGTTGAAGATGGTTCCGTTCAACTAGCAGAC


 


CATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAATAA


 


SEQ ID NO:24


Amino sequence of GFP 1-9 OPT


MRKGEELFTGWPILVELDGDVNGHKFSVRGEGEGDATNGKLSLKFICTTGKLPVPWPTLV


 


TTLTYGVQCFSRYPDHMKRHDFFKSVMPEGYVQERTISFKDDGTYKTPAEVKSEGDTLVN


 


RIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKANFTIRHNVEDGSVQLADH


 


YQQNTPIGDGPVLLPD


 


SEQ ID NO:25


Amino acid sequence of GFP 10-11 OPT


DHYLSTQTILSKDPNEERDHMVLLESVTAAGITHGMDELYK


 


SEQ ID NO:26


Amino acid sequence of NcoI (GFP S10 A4)-KpnI-linker-NdeI-


BamHI-linker-SpeI-(GFP S11 SM5)-NheI-XhoI “10-x-11 sandwich


optimum”.


YTMDLPDDHYLSTQTILSKDLNGTDVGSGGGSHMGGGSGSGGGSGGGSTSEKRDHMVLLE


 


YVTAAGITDAS


 


SEQ ID NO:27


Nucleotide sequence of GFP 1-10 OPT + GFP S11 M2 “GFP 1-10


OPT M2”.


ATGAGCAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGT


 


GATGTTAATGGGCACAAATTTTCTGTCAGAGGAGAGGGTGAAGGTGATGCTACAATCGGA


 


AAACTCACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTT


 


GTCACTACTCTGACCTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAAAGG


 


CATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTC


 


AAAGATGACGGGAAATACAAGACGCGTGCTGTAGTCAAGTTTGAAGGTGATACCCTTGTT


 


AATCGTATCGAGTTAAAGGGTACTGATTTTAAAGAAGATGGAAACATTCTCGGACACAAA


 


CTCGAGTACAACTTTAACTCACACAATGTATACATCACGGCAGACAAACAAAAGAATGGA


 


ATCAAAGCTAACTTCACAGTTCGCCACAACGTTGAAGATGGTTCCGTTCAACTAGCAGAC


 


CATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTAC


 


CTGTCGACACAAACTGTCCTTTCGAAAGATCCCAACGAAAAGCGTGACCACATGGTCCTT


 


CATGAGTCTGTAAATGCTGCTGGGATTACATAA


 


SEQ ID NO:28


Amino acid sequence of GFP 1-10 OPT + GFP S11 M2 “GFP 1-10


OPT M2”.


MSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATIGKLTLKFICTTGKLPVPWPTL


 


VTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGKYKTRAVVKFEGDTLV


 


NRIELKGTDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKANFTVRHNVEDGSVQLAD


 


HYQQNTPIGDGPVLLPDNHYLSTQTVLSKDPNEKRDHMVLHESVNAAGIT*


 


SEQ ID NO:29


Nucleotide acid sequence of GFP 1-10 OPT + GFP S11 M2 + tail


of GFP “GFP 1-10 OPT M2 tailed”.


ATGAGCAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGT


 


GATGTTAATGGGCACAAATTTTCTGTCAGAGGAGAGGGTGAAGGTGATGCTACAATCGGA


 


AAACTCACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTT


 


GTCACTACTCTGACCTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAAAGG


 


CATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTC


 


AAAGATGACGGGAAATACAAGACGCGTGCTGTAGTCAAGTTTGAAGGTGATACCCTTGTT


 


AATCGTATCGAGTTAAAGGGTACTGATTTTAAAGAAGATGGAAACATTCTCGGACACAAA


 


CTCGAGTACAACTTTAACTCACACAATGTATACATCACGGCAGACAAACAAAAGAATGGA


 


ATCAAAGCTAACTTCACAGTTCGCCACAACGTTGAAGATGGTTCCGTTCAACTAGCAGAC


 


CATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTAC


 


CTGTCGACACAAACTGTCCTTTCGAAAGATCCCAACGAAAAGCGTGACCACATGGTCCTT


 


CATGAGTCTGTAAATGCTGCTGGGATTACACATGGCATGGATGAGCTCTACAAATAA


 


SEQ ID NO:30


Amino acid sequence of GFP 1-10 OPT + GFP S11 M2 + tail of


GFP “GFP 1-10 OPT M2 tailed”.


MSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATIGKLTLKFICTTGKLPVPWPTL


 


VTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGKYKTRAVVKFEGDTLV


 


NRIELKGTDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKANFTVRHNVEDGSVQLAD


 


HYQQNTPIGDGPVLLPDNHYLSTQTVLSKDPNEKRDHMVLHESVNAAGITHGMDELYK*


 


SEQ ID NO:31


Nucleotide a sequence of GFP 10-11 OPT.


GACCATTACCTGTCGACACAAACTATCCTTTCGAAAGATCCCAACGAAGAGCGTGACCAC


 


ATGGTCCTTCTTGAGTCTGTAACTGCTGCTGGGATTACACATGGCATGGATGAGCTCTAC


 


AAAT


 


SEQ ID NO:32


Nucleotide sequence of NcoI (GFP S10 A4)-KpnI-linker-NdeI-


BamHI-linker-SpeI-(GFP S11 SM5)-NheI-XhoI “10-x-11 sandwich


optimum”.


GATATACCATGGATTTACCAGACGACCATTACCTGTCGACACAAACTATCCTTTCGAAAG


 


ATCTCAACGGTACCGACGTTGGGTCTGGCGGTGGCTCCCATATGGGTGGCGGTTCTGGAT


 


CCGGTGGAGGGTCTGGTGGCGGATCAACTAGTGAAAAGCGTGACCACATGGTCCTTCTTG


 


AGTATGTAACTGCTGCTGGGATTACAGATGCTAGCTAACTCGAGAATAGC


 


SEQ ID NO:33


Nucleotide sequence of GFP 1-10 OPT + GFP S11 M3 “GFP 1-10


OPT M3”.


ATGAGCAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGT


 


GATGTTAATGGGCACAAATTTTCTGTCAGAGGAGAGGGTGAAGGTGATGCTACAATCGGA


 


AAACTCACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTT


 


GTCACTACTCTGACCTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAAAGG


 


CATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTC


 


AAAGATGACGGGAAATACAAGACGCGTGCTGTAGTCAAGTTTGAAGGTGATACCCTTGTT


 


AATCGTATCGAGTTAAAGGGTACTGATTTTAAAGAAGATGGAAACATTCTCGGACACAAA


 


CTCGAGTACAACTTTAACTCACACAATGTATACATCACGGCAGACAAACAAAAGAATGGA


 


ATCAAAGCTAACTTCACAGTTCGCCACAACGTTGAAGATGGTTCCGTTCAACTAGCAGAC


 


CATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTAC


 


CTGTCGACACAAACTGTCCTTTCGAAAGATCCCAACGAAAAGCGTGACCACATGGTCCTT


 


CATGAGTACGTAAATGCTGCTGGGATTACATAA


 


SEQ ID NO:34


Amino acid sequence of GFP 1-10 OPT + GFP S11 M3 “GFP 1-10


OPT M3”.


MSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATIGKLTLKFICTTGKLPVPWPTL


 


VTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGKYKTRAVVKFEGDTLV


 


NRIELKGTDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKANFTVRHNVEDGSVQLAD


 


HYQQNTPIGDGPVLLPDNHYLSTQTVLSKDPNEKRDHMVLHEYVNAAGIT*


 


SEQ ID NO:35


Nucleotide acid sequence of GFP 1-10 OPT + GFP S11 M3 + tail


of GFP “GFP 1-10 OPT M3 tailed”.


ATGAGCAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGT


 


GATGTTAATGGGCACAAATTTTCTGTCAGAGGAGAGGGTGAAGGTGATGCTACAATCGGA


 


AAACTCACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTT


 


GTCACTACTCTGACCTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAAAGG


 


CATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTC


 


AAAGATGACGGGAAATACAAGACGCGTGCTGTAGTCAAGTTTGAAGGTGATACCCTTGTT


 


AATCGTATCGAGTTAAAGGGTACTGATTTTAAAGAAGATGGAAACATTCTCGGACACAAA


 


CTCGAGTACAACTTTAACTCACACAATGTATACATCACGGCAGACAAACAAAAGAATGGA


 


ATCAAAGCTAACTTCACAGTTCGCCACAACGTTGAAGATGGTTCCGTTCAACTAGCAGAC


 


CATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTAC


 


CTGTCGACACAAACTGTCCTTTCGAAAGATCCCAACGAAAAGCGTGACCACATGGTCCTT


 


CATGAGTACGTAAATGCTGCTGGGATTACACATGGCATGGATGAGCTCTACAAATAA


 


SEQ ID NO:36


Amino acid sequence of GFP 1-10 OPT + GFP S11 M3 + tail of


GFP “GFP 1-10 OPT M3 tailed”.


MSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATIGKLTLKFICTTGKLPVPWPTL


 


VTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGKYKTRAVVKFEGDTLV


 


NRIELKGTDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKANFTVRHNVEDGSVQLAD


 


HYQQNTPIGDGPVLLPDNHYLSTQTVLSKDPNEKRDHMVLHEYVNAAGITHGMDELYK*


 


SEQ ID NO:61


Nucleotide sequence for MTS-SR-s11-6his construct:


ATGTCCGTCCTGACGCCGCTGCTGCTGCGGGGCTTGACAGGCTCGGCCCGGCGGCTCCCA


 


GTGCCGCGCGCCAAGATCCATTCGTTGGGGGACCCACCGGTCGCCACCGGTGGCGGTTCT


 


CATATGCCAGTGAAATGTCCCGGCGAGTACCAAGTTGATGGCAAAAAAGTTATACTAGAC


 


GAGGACTGTTTTATGCAAAACCCAGAGGACTGGGACGAAAAAGTGGCTGAGTGGTTGGCC


 


AGAGAGCTAGAGGGCATACAAAAAATGACCGAGGAGCATTGGAAGTTGGTAAAATACTTA


 


AGGGAGTATTGGGAGACCTTCGGCTCCTGCCCGCCAATTAAAATGGTCACTAAAGAGACG


 


GGCTTCTCCTTGGAGAAAATCTACCAGCTATTCCCCTCGGGGCCTGCGCACGGAGCTTGT


 


AAAGTGGCAGGCGCGCCGAAGCCCACAGGCTGCGTCGGATCCGATGGAGGGTCTGGTGGC


 


GGATCAACAAGCCGTGACCACATGGTCCTTCATGAGTACGTAAATGCTGCTGGGATTACA


 


GGTACCGGTGGCGGTTCTCTCGAGCACCACCACCACCACCACTGA


 


SEQ ID NO:62


Amino-acid sequence for MTS-SR-s11-6his construct


MSVLTPLLLRGLTGSARRLPVPRAKIHSLGDPPVATGGGSHMPVKCPGEYQVDGKKVILD


 


EDCFMQNPEDWDEKVAEWLARELEGIQKMTEEHWKLVKYLREYWETFGSCPPIKMVTKET


 


GFSLEKIYQLFPSGPAHGACKVAGAPKPTGCVGSDGGSGGGSTSRDHMVLHEYVNAAGIT


 


GTGGGSLEHHHHHH*


 


SEQ ID NO:63


Nucleotide sequence for MTS-(1-10) opt-6his construct


ATGTCCGTCCTGACGCCGCTGCTGCTGCGGGGCTTGACAGGCTCGGCCCGGCGGCTCCCA


 


GTGCCGCGCGCCAAGATCCATTCGTTGGGGGACCCACCGGTCGCCACCGGTGGCGGTTCT


 


CATATGATGAGCAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTA


 


GATGGTGATGTTAATGGGCACAAATTTTCTGTCAGAGGAGAGGGTGAAGGTGATGCTACA


 


ATCGGAAAACTCACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCA


 


ACACTTGTCACTACTCTGACCTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCACATG


 


AAAAGGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATA


 


TCTTTCAAAGATGACGGGAAATACAAGACGCGTGCTGTAGTCAAGTTTGAAGGTGATACC


 


CTTGTTAATCGTATCGAGTTAAAGGGTACTGATTTTAAAGAAGATGGAAACATTCTCGGA


 


CACAAACTCGAGTACAACTTTAACTCACACAATGTATACATCACGGCAGACAAACAAAAG


 


AATGGAATCAAAGCTAACTTCACAGTTCGCCACAACGTTGAAGATGGTTCCGTTCAACTA


 


GCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAAC


 


CATTACCTGTCGACACAAACTGTCCTTTCGAAAGATCCCAACGAAAAGGGTACCGGTACC


 


GGTGGCGGTTCTCTCGAGCACCACCACCACCACCACTGA


 


SEQ ID NO:64


Amino-acid sequence for MTS-(1-10) opt-6his construct


MSVLTPLLLRGLTGSARRLPVPRAKIHSLGDPPVATGGGSHMMSKGEELFTGVVPILVEL


 


DGDVNGHKFSVRGEGEGDATIGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHM


 


KRHDFFKSAMPEGYVQERTISFKDDGKYKTRAVVKFEGDTLVNRIELKGTDFKEDGNILG


 


HKLEYNFNSHNVYITADKQKNGIKANFTVRHNVEDGSVQLADHYQQNTPIGDGPVLLPDN


 


HYLSTQTVLSKDPNEKGTGTGGGSLEHHHHHH*


 


SEQ ID NO:65


Receiving vector for nuclear localization (N6his-linker-s11-


SR*)


ATGGGCCACCACCACCACCACCACGGTGGCGGTTCTACTAGTCGTGACCACATGGTCCTT


 


CATGAGTACGTAAATGCTGCTGGGATTACAGGTACCGATGGAGGGTCTGGTGGCGGATCA


 


CATATGCCAGTGAAATGTCCCGGCGAGTACCAAGTTGATGGCAAAAAAGTTATACTAGAC


 


GAGGACTGTTTTATGCAAAACCCAGAGGACTGGGACGAAAAAGTGGCTGAGTGGTTGGCC


 


AGAGAGCTAGAGGGCATACAAAAAATGACCGAGGAGCATTGGAAGTTGGTAAAATACTTA


 


AGGGAGTATTGGGAGACCTTCGGCTCCTGCCCGCCAATTAAAATGGTCACTAAAGAGACG


 


GGCTTCTCCTTGGAGAAAATCTACCAGCTATTCCCCTCGGGGCCTGCGCACGGAGCTTGT


 


AAAGTGGCAGGCGCGCCGAAGCCCACAGGCTGCGTCGGATCCTAACTCGAGCACCACCAC


 


CACCACCACTGA


 


SEQ ID NO:66


AA sequence receiving vector for nuclear localization


(N6his-linker-s11-SR*)


MGHHHHHHGGGSTSRDHMVLHEYVNAAGITGTDGGSGGGSHMPVKCPGEYQVDGKKVILD


 


EDCFMQNPEDWDEKVAEWLARELEGIQKMTEEHWKLVKYLREYWETFGSCPPIKMVTKET


 


GFSLEKIYQLFPSGPAHGACKVAGAPKPTGCVGS*LEHHHHHH*


 


SEQ ID NO:67


Nucleotide sequence for 6his-s11-SR-NLS construct:


ATGGGCCACCACCACCACCACCACGGTGGCGGTTCTACTAGTCGTGACCACATGGTCCTT


 


CATGAGTACGTAAATGCTGCTGGGATTACAGGTACCGATGGAGGGTCTGGTGGCGGATCA


 


CATATGCCAGTGAAATGTCCCGGCGAGTACOAAGTTGATGGCAAAAAAGTTATACTAGAC


 


GAGGACTGTTTTATGCAAAACCCAGAGGACTGGGACGAAAAAGTGGCTGAGTGGTTGGCC


 


AGAGAGCTAGAGGGCATACAAAAAATGACCGAGGAGCATTGGAAGTTGGTAAAATACTTA


 


AGGGAGTATTGGGAGACCTTCGGCTCCTGCCCGCCAATTAAAATGGTCACTAAAGAGACG


 


GGCTTCTCCTTGGAGAAAATCTACCAGCTATTCCCCTCGGGGCCTGCGCACGGAGCTTGT


 


AAAGTGGCAGGCGCGCCGAAGCCCACAGGCTGCGTCGGATCCGGTGGCGGTTCTTCCAAA


 


AAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAA


 


GGTAGGATACACCGGATATAACTCGAG


 


SEQ ID NO:68


Amino-acid sequence for 6his-s11-SR-NLS construct:


MGHHHHHHGGGSTSRDHMVLHEYVNAAGITGTDGGSGGGSHMPVKCPGEYQVDGKKVILD


 


EDCFMQNPEDWDEKVAEWLARELEGIQKMTEEHWKLVKYLREYWETFGSCPPIKMVTKET


 


GFSLEKIYQLFPSGPAHGACKVAGAPKPTGCVGSGGGSSKKEEKGRSKKEEKGRSKKEEK


 


GRIHRI*LE


 


SEQ ID NO:69


Nucleotide sequence for 6his-(1-10opt)-NLS construct:


ATGGGCCACCACCACCACCACCACGGTGGCGGTTCTACTAGTATGAGCAAAGGAGAAGAA


 


CTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGATGTTAATGGGCACAAA


 


TTTTCTGTCAGAGGAGAGGGTGAAGGTGATGCTACAATCGGAAAACTCACCCTTAAATTT


 


ATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTCTGACCTAT


 


GGTGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAAAGGCATGACTTTTTCAAGAGT


 


GCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTCAAAGATGACGGGAAATAC


 


AAGACGCGTGCTGTAGTCAAGTTTGAAGGTGATACCCTTGTTAATCGTATCGAGTTAAAG


 


GGTACTGATTTTAAAGAAGATGGAAACATTCTCGGACACAAACTCGAGTACAACTTTAAC


 


TCACACAATGTATACATCACGGCAGACAAACAAAAGAATGGAATCAAAGCTAACTTCACA


 


GTTCGCCACAACGTTGAAGATGGTTCCGTTCAACTAGCAGACCATTATCAACAAAATACT


 


CCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCGACACAAACTGTC


 


CTTTCGAAAGATCCCAACGAAAAGGGTACCGGATCCGGTGGCGGTTCTTCCAAAAAAGAA


 


GAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGG


 


ATACACCGGATATAACTCGAG


 


SEQ ID NO:70


Amino-acid sequence for 6his-(1-10opt)-NLS construct:


MGHHHHHHGGGSTSMSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATIGKLTLKF


 


ICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGKY


 


KTRAWKFEGDTLVNRIELKGTDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKANFTV


 


RHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQTVLSKDPNEKGTGSGGGSSKKEE


 


KGRSKKEEKGRSKKEEKGRIHRI*LE


 


SEQ ID NO:71


Nucleotide sequence for CAL-SR-s11-6his-KDEL construct:


ATGCTGCTATCCGTGCCGTTGCTGCTCGGCCTCCTCGGCCTGGCCGTCGCCGACCGGTCG


 


CACACCATGGGTGGCGGTTCTCATATGCCAGTGAAATGTCCCGGCGAGTACCAAGTTGAT


 


GGCAAAAAAGTTATACTAGACGAGGACTGTTTTATGCAAAACCCAGAGGACTGGGACGAA


 


AAAGTGGCTGAGTGGTTGGCCAGAGAGCTAGAGGGCATACAAAAAATGACCGAGGAGCAT


 


TGGAAGTTGGTAAAATACTTAAGGGAGTATTGGGAGACCTTCGGCTCCTGCCCGCCAATT


 


AAAATGGTCACTAAAGAGACGGGCTTCTCCTTGGAGAAAATCTACCAGCTATTCCCCTCG


 


GGGCCTGCGCACGGAGCTTGTAAAGTGGCAGGCGCGCCGAAGCCCACAGGCTGCGTCGGA


 


TCCGATGGAGGGTCTGGTGGCGGATCAACAAGCCGTGACCACATGGTCCTTCATGAGTAC


 


GTAAATGCTGCTGGGATTACAGGTACCGGTGGCGGTTCTCTCGAGCACCACCACCACCAC


 


CACGGTGGCGGTTCTAAGGACGAGCTGTAA


 


SEQ ID NO:72


Amino-acid sequence for CAL-SR-s11-6his-KDEL construct:


MLLSVPLLLGLLGLAVADRSHTMGGGSHMPVKCPGEYQVDGKKVILDEDCFMQNPEDWDE


 


KVAEWLARELEGIQKMTEEHWKLVKYLREYWETFGSCPPIKMVTKETGFSLEKIYQLFPS


 


GPAHGACKVAGAPKPTGCVGSDGGSGGGSTSRDHMVLHEYVNAAGITGTGGGSLEHHHHH


 


HGGGSKDEL*


 


SEQ ID NO:73


Nucleotide sequence for CAL-(1-10) opt-6his-KDEL construct:


ATGCTGCTATCCGTGCCGTTGCTGCTCGGCCTCCTCGGCCTGGCCGTCGCCGACCGGTCG


 


CACACCATGGGTGGCGGTTCTCATATGATGAGCAAAGGAGAAGAACTTTTCACTGGAGTT


 


GTCCCAATTCTTGTTGAATTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGAGGA


 


GAGGGTGAAGGTGATGCTACAATCGGAAAACTCACCCTTAAATTTATTTGCACTACTGGA


 


AAACTACCTGTTCCATGGCCAACACTTGTCACTACTCTGACCTATGGTGTTCAATGCTTT


 


TCCCGTTATCCGGATCACATGAAAAGGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGT


 


TATGTACAGGAACGCACTATATCTTTCAAAGATGACGGGAAATACAAGACGCGTGCTGTA


 


GTCAAGTTTGAAGGTGATACCCTTGTTAATCGTATCGAGTTAAAGGGTACTGATTTTAAA


 


GAAGATGGAAACATTCTCGGACACAAACTCGAGTACAACTTTAACTCACACAATGTATAC


 


ATCACGGCAGACAAACAAAAGAATGGAATCAAAGCTAACTTCACAGTTCGCCACAACGTT


 


GAAGATGGTTCCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGC


 


CCTGTCCTTTTAGCAGACAACCATTACCTGTCGACACAAACTGTCCTTTCGAAAGATCCC


 


AACGAAAAGGGTACCGGTACCGGTGGCGGTTCTCTCGAGCACCACCACCACCACCACGGT


 


GGCGGTTCTAAGGACGAGCTGTAA


 


SEQ ID NO:74


Amino-acid sequence for CAL-(1-10) opt-6his-KDEL construct:


MLLSVPLLLGLLGLAVADRSHTMGGGSHMMSKGEELFTGVVPILVELDGDVNGHKFSVRG


 


EGEGDATIGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEG


 


YVQERTISFKDDGKYKTRAVVKFEGDTLVNRIELKGTDFKEDGNILGHKLEYNFNSHNVY


 


ITADKQKNGIKANFTVRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQTVLSKDP


 


NEKGTGTGGGSLEHHHHHHGGGSKDEL*

## Claims

1. An assay for detecting the localization of a test protein, X, to a subcellular component of interest in a cell, comprising:
(a) expressing in the cell or providing to the cell (i) a fusion protein comprising the test protein, X, and a microdomain tag fragment of a fluorescent protein, wherein the microdomain tag fragment corresponds to one or more contiguous beta-strands of the fluorescent protein, and (ii) a complementary assay fragment of the fluorescent protein functionalized to be directed and localized to the subcellular component of interest, wherein the assay fragment corresponds to the remaining contiguous beta-strands of the fluorescent protein, and wherein the microdomain tag and complementary assay fragments self-complement to reconstitute the fluorescent protein if present in the same subcellular component; and,
(b) detecting fluorescence in the cell, and thereby detecting the localization of the test protein, X, to the subcellular component of interest.

2. The assay according to claim 1, wherein the cell is a eukaryotic cell.

3. The assay according to claim 1 or 2, wherein the microdomain tag fragment corresponds to a single beta-strand of the fluorescent protein, and the assay fragment corresponds to the remaining ten beta-strands of the fluorescent protein.

4. The assay according to claim 3, wherein the microdomain tag fragment corresponds to beta-strand s11 and the assay fragment corresponds to beta-strands s1-10.

5. The assay according to claim 4, wherein the microdomain tag fragment is selected from the group consisting of SEQ ID NOS: 12, 14 and 16.

6. The assay according to claim 4, wherein the assay fragment is selected from the group consisting of SEQ ID NOS: 4 and 6.

7. The assay according to claim 1 or 2, wherein the assay fragment is fused in appropriate orientation to a polypeptide localization signal capable of directing and localizing the assay fragment to the nucleus, cytoplasm, plasma membrane, endoplasmic reticulum, golgi apparatus, actin and tubulin filaments, endosomes, peroxisomes or mitochondria.

8. The assay according to claim 7, wherein the fusion protein comprising the test protein X and the microdomain tag fragment further comprises an appropriately oriented localization signal capable of directing and localizing the fusion protein to the same subcellular compartment to which the assay fragment is directed.

9. An assay for detecting the localization of a test protein, X, to one or more of a plurality of subcellular components of interest in a cell, comprising:
(a) expressing in the cell or providing to the cell (i) a fusion protein comprising the test protein, X, and a microdomain tag fragment of a fluorescent protein, wherein the microdomain tag fragment corresponds to one or more contiguous beta-strands of the fluorescent protein, and (ii) a plurality of complementary assay fragments of the fluorescent protein, wherein each of which assay fragments corresponds to the remaining contiguous beta-strands of the fluorescent protein, is functionalized to be directed and localized to a different subcellular component of interest, designed or selected to produce different color fluorescence upon complementation with the microdomain tag fragment, and complements with the microdomain tag fragment to reconstitute the fluorescent protein, if present in the same subcellular component; and,
(b) detecting the various color fluorescence signals in cell, and thereby detecting the localization of the test protein, X, to one or more of the subcellular components of interest.

10. The assay according to claim 9, wherein the cell is a eukaryotic cell.

11. The assay according to claim 9 or 10, wherein the microdomain tag fragment corresponds to a single beta-strand of the fluorescent protein, and the assay fragment corresponds to the remaining ten beta-strands of the fluorescent protein.

12. The assay according to claim 11, wherein the microdomain tag fragment corresponds to beta-strand all and the assay fragments corresponds to beta-strands s1-10.

13. The assay according to claim 12, wherein the microdomain tag fragment is selected from the group consisting of SEQ ID NOs: 12, 14 and 16.

14. The assay according to claim 12, wherein the assay fragments are selected from the group consisting of SEQ ID NOs: 4 and 6.